

# 第2日

D A Y 2

2月18日(金)

Friday, February 18, 2022

## Presidential Session

**PS3** Presidential Session 3..... 161

## Asia-Pacific/JSMO Joint Symposium / Asia-Pacific/JSMO 合同シンポジウム

**APJS** Pan-Asian Clinical Trial..... 180

## Joint Symposium / 合同シンポジウム

**JS3** Rethinking the Integration of Oncology and Palliative Care  
あらためて、緩和ケアとオンコロジーのインテグレーションを考える..... 192

## Presidential Symposium / 会長企画シンポジウム

**PSY4** Cancer Genomics (Past, Present & Future)  
がんゲノム医療(これまでとこれから)..... 162

**PSY5** Supportive & Palliative Care: Consensus symposium on guidelines for research on  
dyspnea  
支持緩和領域：呼吸困難に関する研究の指針についてのコンセンサスシンポジウム... 172

**PSY6** UPDATE on Cancer of Unknown Primary  
原発不明がんUPDATE..... 180

## Symposium / シンポジウム

**SY13** How to enhance the capability for leading international clinical trials  
国際共同研究をリードする日本の臨床研究力..... 168

**SY14** Future Perspective of Breast Cancer Immunotherapy  
乳癌免疫療法の今後の展開..... 169

**SY15** Results and Issues of Palliative Care Clinical Trials (from Cancer Pain Guidelines and  
Early Palliative Care)- Toward Integration of Basic and Clinical Medicine  
がん疼痛ガイドラインと早期緩和ケアから見える臨床試験の結果と課題～基礎・臨床医学  
の統合を目指して～..... 171

**SY16** Discuss task sharing/shifting in cancer care  
多職種で考えるがん領域のタスクシェアリング/タスクシフティング..... 173

**SY17** Optimal treatment strategy for locally advanced head and neck cancer  
局所進行頭頸部がんに対する最適な治療戦略..... 176

**SY18** PARP inhibitor for Ovarian Cancer Treatment..... 179

**SY19** Cutting edge of treatment for colorectal cancer -current status and future perspective  
標的分子からみた大腸癌治療の現状と展望..... 181

**SY20** Development of treatment for patients with non-small cell lung cancer harboring rare  
driver mutations  
比較的稀なドライバー遺伝子変異陽性肺癌に対する治療開発..... 189

**SY21** RAS/RAF pathway-altered cancers..... 189

<b>SY22</b>	Future challenge of liquid biopsy for next generation cancer therapeutics.....	190
<b>SY23</b>	Encyclopedic Seamless Drug Development for Organ Agnostic Oncology Precision Medicine - Frontline therapeutics of targeting BRCA (HRD), PARP, HER2 and NTRK genetic alteration .....	191

Educational Lecture / 教育講演

<b>EL15</b>	応用編 肝臓癌.....	164
<b>EL16</b>	応用編 乳癌(周術期薬物療法).....	164
<b>EL17</b>	応用編 乳癌(転移・再発薬物療法).....	164
<b>EL18</b>	応用編 子宮頸癌・子宮体癌.....	164
<b>EL19</b>	応用編 卵巣癌.....	165
<b>EL20</b>	応用編 小細胞肺癌・中皮腫.....	165
<b>EL21</b>	応用編 非小細胞肺癌.....	165
<b>EL22</b>	応用編 泌尿器癌(腎、尿路、前立腺).....	165

Meet the Experts

<b>ME06</b>	Developments of novel therapies in Gastrointestinal Stromal Tumor(GIST): Looking towards the future and learning from the past .....	194
<b>ME07</b>	New treatment strategy for hepatobiliary cancer.....	194
<b>ME08</b>	Revolutionizing the treatment of small cell lung cancer.....	194
<b>ME09</b>	Perspectives for clinical trials in upper GI cancer.....	194
<b>ME10</b>	Liquid biopsy in the era of precision oncology .....	195
<b>ME11</b>	The role of exercise in cancer survivorship: Past, present and future.....	195

JSMO Membership Committee Program・Career Empowerment Committee Program /

日本臨床腫瘍学会会員委員会・キャリアエンパワーメント委員会合同企画

<b>MC</b>	Investigation of the effects of COVID-19 on chemotherapy for malignancies and its future perspective・Discuss the Need for Career Counseling! COVID-19によるがん薬物療法の影響調査と今後の展開・キャリア相談に関するニーズ についてディスカッションする！.....	178
-----------	--	-----

JSMO Committee on Guideline Program / 日本臨床腫瘍学会 ガイドライン委員会企画

<b>GL1</b>	Outline of the Clinical Practice Guidelines for Tumor-Agnostic Treatments in Adult and Pediatric Patients with Advanced Solid Tumors toward Precision Medicine (3rd Edition) 成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン(第3版)の概要 ..	186
<b>GL2</b>	About the Practical Guideline of Bone Metastasis, Revised 2nd Edition 骨転移診療ガイドライン改訂第2版について.....	186

Highlight of the Day

<b>HoD1</b>	Highlight of the Day 1.....	162
-------------	-----------------------------	-----

## 第1会場 (国立京都国際会館 1階 メインホール)

8:20-10:35 Presidential Session 3

### PS3 Presidential Session 3



Chairs : Chikashi Ishioka (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)  
Ian Chau (Department of Medicine, Royal Marsden Hospital, London&Surrey, United Kingdom)  
司会 : 石岡 千加史 (東北大学大学院医学系研究科臨床腫瘍学分野)  
Ian Chau (Department of Medicine, Royal Marsden Hospital, London&Surrey, United Kingdom)

#### PS3-1 **First-line nivolumab plus ipilimumab or chemotherapy for advanced ESCC: A Japanese subanalysis of CheckMate 648**

Takashi Ogata (Kanagawa Cancer Center)  
尾形 高士 (神奈川県立がんセンター)

Discussant : Sun Young Rha (Yonsei Cancer Center, Yonsei University)  
Yasuo Hamamoto (Keio Cancer Center, Keio University School of Medicine)

ディスカッション: Sun Young Rha (Yonsei Cancer Center, Yonsei University)  
浜本 康夫 (慶應義塾大学 医学部)

#### PS3-2 **A randomized controlled trial of neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study**

Encore

Ken Kato (Department of Head and Neck, Esophageal Medical Oncology)

**臨床病期IB/II/III食道癌(T4を除く)に対する術前CF療法/術前DCF療法/術前CF-RT療法の第III相比較試験 JCOG1109 NExT試験**

加藤 健 (国立がん研究センター中央病院 頭頸部・食道内科)

Discussant : Ian Chau (Department of Medicine, Royal Marsden Hospital, London & Surrey, United Kingdom)  
Kenro Hirata (Cancer Center, Keio University)

ディスカッション: Ian Chau (Department of Medicine, Royal Marsden Hospital, London & Surrey, United Kingdom)  
平田 賢郎 (慶應義塾大学 医学部腫瘍センター)

#### PS3-3 **Post-operative genomic/epigenomic signatures of circulating tumor DNA and recurrence in colorectal cancer: COSMOS-CRC-01**

Yoshiaki Nakamura (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

**大腸癌治療切除後患者における血中循環腫瘍DNAのゲノム・エピゲノム統合解析—COSMOS-CRC-01**

中村 能章 (国立がん研究センター東病院消化管内科)

Discussant : Zev A. Wainberg (UCLA School of Medicine)  
TBD

ディスカッション: Zev A. Wainberg (UCLA School of Medicine)  
調整中

#### PS3-4 **Oxaliplatin with FU plus BEV in elderly pts with metastatic colorectal cancer: a phase III trial of JCOG1018 (RESPECT)**

Atsuo Takashima (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

高島 淳生 (国立がん研究センター中央病院 消化管内科)

Discussant : Eric Van Cutsem (University Hospitals Gasthuisberg / Leuven & KULeuven)  
Hironaga Satake (Department of Medical Oncology, Kochi Medical School)

ディスカッション: Eric Van Cutsem (University Hospitals Gasthuisberg / Leuven & KULeuven)  
佐竹 悠良 (高知大学 医学部腫瘍内科学講座)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

PS3-5 **A phase III trial of adjuvant S-1 vs. observation for resected biliary tract cancer: JCOG1202, ASCOT**

**Encore**  
 Akiko Todaka (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
 戸高 明子 (静岡県立静岡がんセンター 消化器内科)  
 Discussant : Yoo Changhoon (Asan Medical Center)  
 Etsuro Hatano (Department of Surgery, Graduate School of Medicine, Kyoto University)  
 ティスカガホーン : Yoo Changhoon (Asan Medical Center)  
 波多野 悦朗 (京都大学 肝胆脾・移植外科)

13:45-15:00 Highlight of the Day 1

**HoD1 Highlight of the Day 1**

Chairs : Yuichiro Ohe (Department of Thoracic Oncology, National Cancer Center Hospital)  
 Hiroji Iwata (Department of Breast Oncology, Aichi Cancer Center Hospital)  
 司会 : 大江 裕一郎 (国立がん研究センター中央病院 呼吸器内科)  
 岩田 広治 (愛知県がんセンター 乳腺科)

HoD1-1 **Hepatobiliary / Pancreatic Cancer**  
 Takuji Okusaka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)  
**肝胆脾**  
 奥坂 拓志 (国立がん研究センター中央病院 肝胆脾内科)

HoD1-2 **Breast Cancer**  
 Fumikata Hara (Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR)  
**乳腺**  
 原文 堅 (がん研究会有明病院 乳腺内科)

HoD1-3 **Genitourinary Cancer**  
 Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)  
**泌尿器**  
 北村 寛 (富山大学 学術研究部医学系 腎泌尿器科学)

HoD1-4 **Multidisciplinary Team Program**  
 Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center)  
**多職種連携プログラム**  
 高橋 将人 (国立病院機構北海道がんセンター 乳腺外科)

15:05-16:35 Presidential Symposium 4 / 会長企画シンポジウム 4

**PSY4 Cancer Genomics (Past, Present & Future)**  
**がんゲノム医療(これまでとこれから)** E

Chair : Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)  
 司会 : 山本 昇 (国立がん研究センター中央病院 先端医療科)

PSY4-1 **The current status of precision oncology in Japan**  
 Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)  
**がんゲノム医療の現状**  
 角南 久仁子 (国立がん研究センター中央病院 臨床検査科)

PSY4-2 **Prospective of patient-proposal healthcare services with multiple targeted agents**  
Yayoi Ando (Clinical Research Support office Clinical Trial Management Section, National Cancer Center Hospital)

**がんゲノム医療に基づいた患者申出療養の先にあるもの**  
安藤 弥生 (国立がん研究センター中央病院 臨床研究支援室)

PSY4-3 **Discussion on the Appropriate Timing of Comprehensive Genomic Profiling Test in Japan**

Manabu Muto (Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine)

**わが国におけるがん遺伝子パネル検査のタイミングに関する考察**  
武藤 学 (京都大学大学院医学研究科 腫瘍薬物治療学)

PSY4-4 **Implementation of whole genome sequence into clinical practice**  
Emile Voest (The Netherlands Cancer Institute, Amsterdam, The Netherlands)

PSY4-5 **Future perspective of genome-based medicine in Japan**  
Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)

**日本のがんゲノム医療の今後**  
山本 昇 (国立がん研究センター中央病院 先端医療科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

**第2+3会場 (国立京都国際会館 1階 Annex 1+2)**

8:20-8:50 Educational Lecture 15 / 教育講演 15

**EL15** 応用編 肝臓癌

**Systemic therapy for hepatocellular carcinoma**

Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

**肝細胞癌の薬物療法**

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

8:50-9:20 Educational Lecture 16 / 教育講演 16

**EL16** 応用編 乳癌(周術期薬物療法)

**Breast Cancer (Perioperative medical treatment)**

Fumikata Hara (Japanese Foundation for Cancer Research Cancer Institute Hospital)

**乳癌(周術期薬物療法)**

原文堅 (がん研究会有明病院 乳腺内科)

9:20-9:50 Educational Lecture 17 / 教育講演 17

**EL17** 応用編 乳癌(転移・再発薬物療法)

**Breast cancer (management for recurrent or metastatic breast cancer)**

Yoichi Naito (Department of General Internal Medicine, National Cancer Center Hospital East)

**乳癌(転移・再発薬物療法)**

内藤 陽一 (国立がん研究センター東病院 総合内科)

9:50-10:20 Educational Lecture 18 / 教育講演 18

**EL18** 応用編 子宮頸癌・子宮体癌

**New treatment option of cervical cancer and endometrial cancer**

Mayu Yunokawa (Department of Gynecology Oncology, and Department of Medical Oncology, Cancer Institute Hospital of JFCR)

**子宮頸癌・子宮体癌の新規治療選択肢**

温泉川 真由 (がん研究会有明病院 婦人科 兼 総合腫瘍科)

10:20-10:50 Educational Lecture 19 / 教育講演 19

EL19 応用編 卵巣癌

### Ovarian Cancer

Kenichi Harano (Department of Experimental Therapeutics/Medical Oncology, National Cancer Center Hospital East)

#### 卵巣癌

原野 謙一 (国立がん研究センター東病院 先端医療科/腫瘍内科)

10:50-11:20 Educational Lecture 20 / 教育講演 20

EL20 応用編 小細胞肺癌・中皮腫

### Small cell lung cancer and malignant mesothelioma

Kiichiro Ninomiya (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

#### 小細胞肺癌・中皮腫

二宮 貴一朗 (岡山大学学術研究院医歯薬学域 血液・腫瘍・呼吸器内科学)

14:05-14:35 Educational Lecture 21 / 教育講演 21

EL21 応用編 非小細胞肺癌

### Overview of the development in the treatment for non-small cell lung cancer

Satoru Miura (Niigata Cancer Center Hospital)

#### 非小細胞肺癌治療の進歩

三浦 理 (新潟県立がんセンター新潟病院)

14:35-15:05 Educational Lecture 22 / 教育講演 22

EL22 応用編 泌尿器癌(腎、尿路、前立腺)

### Systemic therapy for genitourinary cancers

Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)

#### 泌尿器がんの薬物療法

北村 寛 (富山大学 学術研究部医学系 腎泌尿器科学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

15:05-16:35 Oral Session 8

08

Lung Cancer / Thoracic Cancer 2 (Immune Checkpoint Inhibitors)  
 呼吸器2(免疫チェックポイント阻害薬)



Chairs : Isamu Okamoto (Research Institute for Diseases of the Chest, Kyushu University)  
 Kazuhisa Takahashi (Department of Respiratory Medicine, Juntendo University)  
 Discussant : Tatsuya Yoshida (Department of Thoracic Oncology, National Cancer Center Hospital)  
 司会 : 岡本 勇 (九州大学大学院医学研究院 呼吸器内科学分野)  
 高橋 和久 (順天堂大学医学部呼吸器内科学)  
 ディスカッサント: 吉田 達哉 (国立がん研究センター中央病院 呼吸器内科)

08-1 **First-line nivolumab + platinum chemotherapy + bevacizumab in advanced NSQ NSCLC: Subgroup analysis on OS in TASUKI-52**

Naoki Inui (Department of Pulmonary Medicine, Hamamatsu University Hospital)  
 乾 直輝 (浜松医科大学医学部附属病院 呼吸器内科)

08-2 **Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study**

Encore

Haruhiro Saito (Kanagawa Cancer Center)  
 齋藤 春洋 (神奈川県立がんセンター)

08-3 **Pembrolizumab Plus Chemo in Asian Patients With PD-L1 Negative Advanced NSCLC: Pooled Analysis of KN021G, 189 and 407**

Encore

Takayasu Kurata (Department of Thoracic Oncology, Kansai Medical University Hospital)  
 倉田 宝保 (関西医科大学附属病院 呼吸器腫瘍内科)

08-4 **KEYNOTE-042: 5-Year Update of 1L Pembrolizumab in Asian Patients With Locally Advanced/Metastatic PD-L1-Positive NSCLC**

Kaoru Kubota (Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital)  
 久保田 馨 (日本医科大学付属病院 呼吸器内科/化学療法科)

08-5 **First-line nivolumab (N) + ipilimumab (I) in unresectable malignant pleural mesothelioma (MPM): CheckMate 743 3-y data**

Encore

Nobukazu Fujimoto (Department of Medical Oncology, Okayama Rosai Hospital)  
 藤本 伸一 (岡山労災病院 腫瘍内科)

08-6 **KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma in Japan**

Takashi Kijima (Department of Respiratory Medicine and Hematology, Hyogo College of Medicine)  
 木島 貴志 (兵庫医科大学病院 呼吸器内科)



## 第4会場 (国立京都国際会館 2階 Room A)

8:20-9:10 Mini-Oral Session 20

**MO20** Translational Research / Clinical Pharmacology 3(Biomarker)  
TR・臨床薬理3(バイオマーカー)

**E**

Chairs : Hiroshi Ishiguro (Breast Oncology Service, Saitama Medical University International Medical Center)  
Natsuko Chiba (Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University)  
司会 : 石黒 洋 (埼玉医科大学 国際医療センター 乳腺腫瘍科)  
千葉 奈津子 (東北大学加齢医学研究所 腫瘍生物学分野)

### MO20-1 Characterization of OASEP1 as a potential prognostic biomarker and therapeutic target for oral cancer

Atsushi Takano (Ctr. Antibody and Vaccine Ther, Inst. Med. Sci., Univ. of Tokyo / Dep. Med. Oncol. & Cancer Ctr., Shiga Univ. Med. Sci. / Ctr. Advanced Med. against Cancer, Shiga Univ. of Med. Sci.)  
高野 淳 (東京大学医科学研究所附属病院 抗体ワクチンセンター／滋賀医科大学 臨床腫瘍学講座・腫瘍センター／滋賀医科大学 先端がんセンター)

### MO20-2 Efficacy of Immune Checkpoint Inhibitors for Gastrointestinal Cancers with SWI/SNF Complex Genetic Alterations

Akinobu Nakata (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
中田 晃暢 (愛知県がんセンター病院 薬物療法部)

### MO20-3 Caffeic acid phenethyl ester suppresses drug resistance of enzalutamide or abiraterone in prostate cancer cells

Chih-Pin Chuu (Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan)

### MO20-4 BRCA1-mediated transactivation causes resistance to PARP inhibitors without affecting homologous recombination activity

Natsuko Chiba (Department of Cancer Biology, IDAC, Tohoku University)

#### BRCA1の転写の活性化能によるPARP阻害薬への耐性機構

千葉 奈津子 (東北大学加齢医学研究所 腫瘍生物学分野)

### MO20-5 KRAS inhibitor-resistance in MET-amplified KRASG12C NSCLC induced by RAS- and non-RAS-mediated cell signaling mechanisms

Shinichiro Suzuki (Department of Medical Oncology, Kindai University Faculty of Medicine)  
鈴木 慎一郎 (近畿大学 医学部内科学腫瘍内科部門)

### MO20-6 CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis

Aya Fukuizumi (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School)  
福泉 彩 (日本医科大学大学院医学研究科呼吸器内科学分野)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

9:10-10:40 Symposium 13 / シンポジウム 13

**SY13** How to enhance the capability for leading international clinical trials  
国際共同研究をリードする日本の臨床研究力



Chairs : Masaru Iwasaki (Center for Advancing Clinical Research, University of Yamanashi)  
Shogo Nomura (Department of Biostatistics and Bioinformatics, The University of Tokto)  
司会 : 岩崎 甫 (山梨大学 融合研究臨床応用推進センター)  
野村 尚吾 (東京大学大学院医学系研究科 生物統計情報学講座)

SY13-1 **The application of "Liquid Biopsies" in the search of molecular targets : The great Equalizer for International Trial Collaboration**  
Tanios S. Bekaii-Saab (Mayo Clinic Cancer Center)

SY13-2 **Global Advanced/Adjuvant Stomach Tumor Research International Collaboration through Individual Patient based Data Meta-analysis: GASTRIC project**  
Koji Oba (Department of Biostatistics, the University of Tokyo)  
**進行・再発胃がん、術後胃癌を対象とした個人ベースの国際共同メタアナリシス研究 : GASTRIC project**  
大庭 幸治 (東京大学大学院 情報学環 / 医学系研究科 生物統計学分野)

SY13-3 **SCRUM-Japan adaptive platform trials to accelerate precision oncology innovations**  
Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Japan)  
**SCRUM- Japan; Precision Oncologyを革新的に加速するプラットフォーム**  
吉野 孝之 (国立がん研究センター東病院 消化管内科)

SY13-4 **Global collaboration in clinical development for gynecological cancer and the current status in Japan**  
Kosei Hasegawa (Department of Gynecologic Oncology, Saitama Medical University International Medical Center)  
**婦人科がん領域の臨床開発における国際協力と日本の現状**  
長谷川 幸清 (埼玉医科大学国際医療センター)

SY13-5 **Future perspectives of required multiple infrastructures for achieving sustainable implementation of global first-in-human phase 1 trials in Japan**  
Toshio Shimizu (Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital)  
**変遷するがん新薬早期開発 - 我が国が恒常的にFirst-in-Human (FIH) Phase 1 を実践するために - 現状と課題**  
清水 俊雄 (国立がん研究センター中央病院 先端医療科)

14:05-14:55 Mini-Oral Session 21

**MO21** Gastrointestinal Cancer 2(Upper GI Tract 2)  
消化器2(上部消化管2)



Chairs : Hiroshi Imazeki (Clinical Trial Promotion Department, Chiba Cancer Center)  
Hitoshi Kusaba (Department of Medicine and Comprehensive Biosystemic Science, Kyushu University)  
司会 : 今関 洋 (千葉県がんセンター 治験臨床試験推進部)  
草場 仁志 (九州大学 血液腫瘍・心血管内科)

**MO21-1** **FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma**

Encore

Yue Wang (The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School)

**MO21-2** **Correlation of response following NACT between FDG PETCT and TRG in SCC of esophagus A prospective study**

Naveen Kumar (Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India)

**MO21-3** **Altered fecal microbiota signatures in patients with anxiety and depression in the gastrointestinal cancer screening**

Juan Zhu (National Cancer Registry Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)

**MO21-4** **Microbial Biomarker and Epidemiological Factor to Identify Esophageal Squamous Cell Carcinoma and Precancerous Lesions**

Minjuan Li (National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)

**MO21-5** **Association of CD4/CD8 ratio with survival and response to ICIs in patients with advanced gastric and esophageal cancer**

Junjie Hang (Department of Medical Oncology, Changzhou No.2 People's Hospital)

**MO21-6** **Decrease of soluble CTLA4 is a significant better prognostic marker in nivolumab treatment of advanced gastric cancer**

Kotoe Oshima (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
大嶋 琴絵 (国立がん研究センター中央病院 消化管内科)

15:05-16:35 Symposium 14/シンポジウム 14

**SY14** Future Perspective of Breast Cancer Immunotherapy  
乳癌免疫療法の今後の展開



Chairs : Shigehira Saji (Department of Medical Oncology, Fukushima Medical University)  
Yukinori Ozaki (Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
司会 : 佐治 重衡 (福島県立医科大学 腫瘍内科学)  
尾崎 由記範 (がん研究会有明病院 乳腺内科)

**SY14-1** **Future perspectives immunotherapy in breast cancer**

Rebecca Dent (National Cancer Centre Singapore)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

SY14-2 **Strategies for cancer immunotherapy based on breast cancer microenvironment**  
Shigehisa Kitano (The Cancer Institute Hospital of JFCR)

**乳癌微小環境から考察するがん免疫療法の戦略**  
北野 滋久 (がん研究会有明病院)

SY14-3 **Immunotherapeutic strategies for each breast cancer subtype**  
Fumikata Hara (Japanese Foundation for Cancer Research Cancer Institute Hospital)

**乳癌サブタイプ毎の免疫治療戦略**  
原 文堅 (がん研究会有明病院)

SY14-4 **Cutting edge developments in Immuno-Oncology Biomarkers**  
Tomoharu Sugie (Breast Surgery, Kansai Medical University Hospital)

**免疫治療バイオマーカー最前線**  
杉江 知治 (関西医科大学附属病院 乳腺外科)

## 第5会場 (国立京都国際会館 2階 Room B-1)

8:20-9:50 Symposium 15 / シンポジウム 15

- SY15** Results and Issues of Palliative Care Clinical Trials (from Cancer Pain Guidelines and Early Palliative Care)- Toward Integration of Basic and Clinical Medicine  
がん疼痛ガイドラインと早期緩和ケアから見える臨床試験の結果と課題～基礎・臨床医学の統合を目指して～
- Chairs : Eriko Satomi (Department of Palliative Medicine, National Cancer Center Hospital)  
Masakazu Abe (Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine)
- 司会 : 里見 絵理子 (国立がん研究センター中央病院 緩和医療科)  
安部 正和 (浜松医科大学医学部付属病院 産科婦人科)
- 
- SY15-1** **Clinical issues that cannot be recommended in clinical guidelines - How to choose between the opioids available**  
Kinomi Yomiya (Department of Palliative Care, Saitama cancer center)  
**ガイドラインでは提示できない臨床的課題—強オピオイド鎮痛薬の選択、および末梢性 $\mu$ オピオイド受容体拮抗薬の位置づけ—**  
余宮 きのみ (埼玉県立がんセンター 緩和ケア科)
- 
- SY15-2** **Comparing morphine with oxycodone for cancer pain using a catechol-O-methyltransferase genotype biomarker (RELIEF study): A randomized clinical trial**  
Hiromichi Matsuoka (Department of Psychosomatic Medicine, Kindai University Faculty of Medicine / Department of Psycho-Oncology, Palliative Care Team, National Cancer Center Hospital / Palliative Care Center, Kindai Hospital)  
**がん疼痛に対するオピオイド選択のためのバイオマーカーを用いたランダム化比較試験 (Relief Study)**  
松岡 弘道 (近畿大学医学部内科学心療内科部門 / 国立がん研究センター中央病院精神腫瘍科 / 緩和ケアチーム / 近畿大学病院緩和ケアセンター)
- 
- SY15-3** **Neuropathic pain mechanisms uncovered by neuron-glia interactions**  
Makoto Tsuda (Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University)  
**神経—グリア相互連関からわかってきた神経障害性疼痛メカニズム**  
津田 誠 (九州大学 大学院薬学研究院 薬理学分野)
- 
- SY15-4** **Assessment of appropriate referral timing to Specialized Palliative Care service based on the survey of bereaved families of cancer patients**  
Keita Tagami (Department of Palliative Medicine, Tohoku University Graduate School of Medicine)  
**がん患者の遺族調査から、がん治療と専門的緩和ケアサービスの適切な連携タイミングをアセスメントする**  
田上 恵太 (東北大学大学院 医学系研究科 緩和医療学分野)
- 
- SY15-5** **Researches on Palliative Care Delivery: Present and Future**  
Yoshihisa Matsumoto (Department of Palliative Medicine, National Cancer Center Hospital East)  
**緩和ケアデリバリーに関する研究：現在と今後**  
松本 禎久 (国立がん研究センター東病院 緩和医療科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

9:50-11:20 Presidential Symposium 5 / 会長企画シンポジウム 5

**PSY5** Supportive & Palliative Care: Consensus symposium on guidelines for research on dyspnea  
 支持緩和領域：呼吸困難に関する研究の指針についてのコンセンサスシンポジウム

Chairs : Yosuke Uchitomi (Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center)  
 Kazuo Tamura (School of Medicine, Fukuoka University)  
 司会 : 内富 庸介 (国立がん研究センター中央病院 支持療法開発部門)  
 田村 和夫 (福岡大学 医学部)

PSY5-1 **The project of making research policy of supportive and palliative care In Japan**  
 Sadamoto Zenda (Department of Radiation Oncology, National Cancer Center Hospital East)  
**支持療法・緩和治療領域研究ポリシー**  
 全田 貞幹 (国立がん研究センター東病院 放射線治療科)

PSY5-2 **Dyspnea, its assessment tools, and related causes and factors in cancer patients**  
 Yoshinobu Matsuda (Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center)  
**がん患者の呼吸困難と評価尺度と関連する原因・因子**  
 松田 能宣 (国立病院機構近畿中央呼吸器センター 心療内科)

PSY5-3 **Research policy for cancer dyspnea: Dyspnea at rest**  
 Masanori Mori (Palliative and Supportive Care Division, Seirei Mikatahara General Hospital)  
**がん呼吸困難に関する研究の指針：安静時呼吸困難**  
 森 雅紀 (聖隷三方原病院 緩和と支持治療科)

PSY5-4 **Research policy for cancer dyspnea: Exertional dyspnea**  
 Takashi Yamaguchi (Department of Palliative Medicine, Kobe University)  
**がん呼吸困難に関する研究指針：労作時呼吸困難**  
 山口 崇 (神戸大学医学部附属病院 緩和と支持治療科)

14:05-14:55 Mini-Oral Session 22

**MO22 COVID-19 1** E

Chairs : Nobuaki Kobayashi (Department of Pulmonology, Yokohama City University Graduate School of Medicine)  
 Daisuke Himeji (Endoscopy Center, Miyazaki Prefectural Miyazaki Hospital)  
 司会 : 小林 信明 (横浜市立大学大学院医学研究科 呼吸器病学)  
 姫路 大輔 (県立宮崎病院 内視鏡センター)

MO22-1 **Outcomes and Risk Factors of Patients with COVID-19 and Cancer (ONCORONA): A Sub-study of the Philippine CORONA study**  
 Ramon Jr B. Larrazabal (Division of Medical Oncology, Department of Medicine, Philippine General Hospital)

MO22-2 **Thromboembolic events associated to COVID-19 in a breast cancer cohort during the most recent waves of the disease**  
 Jorge Illarramendi (Service of Hematology, University Hospital of Navarre)

MO22-3 **Gravity of Covid 19 infection in oncology patients undergoing active treatment , a Romanian Cancer Center experience**  
 Ramona Matei (Department of Medical Oncology, Clinical Municipal Hospital Cluj Napoca)

M022-4 **Impact of the COVID-19 Pandemic on the Treatment Schedules of Cancer Patients Receiving Systemic Treatment**  
Aylmer Rex B. Hernandez (Division of Medical Oncology, Department of Medicine, University of the Philippines, Manila, Philippines)

M022-5 **COVID-19 lockdown: Psychological impact on breast Cancer patients**  
Shekhar Goyal (Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida, Uttar Pradesh, India / Department of Oncology, ATRCTRI, S.P. Medical College & AG of Hospitals, Bikaner-334003, Rajasthan, India)

15:05-16:35 Symposium 16 / シンポジウム 16

**SY16** Discuss task sharing/shifting in cancer care  
多職種で考えるがん領域のタスクシェアリング / タスクシフティング

Chairs : Taito Esaki (Clinical Research Institute, Kyushu Cancer Center)  
Tomoaki Yoshimura (Department of Pharmacy, Ogaki Municipal Hospital)  
司会 : 江崎 泰斗 (九州がんセンター 臨床研究センター)  
吉村 知哲 (大垣市民病院 薬剤部)

SY16-1 **Task sharing and shifting to provide a better quality cancer care in Japan**  
Takeyuki Wada (Department of Gastric Surgery, National Cancer Center Hospital)  
**よりQualityの高いがん治療を実現するためのタスクシェアリング / タスクシフティング**  
和田 剛幸 (国立がん研究センター中央病院 胃外科)

SY16-2 **Task sharing/shifting to pharmacists in cancer care**  
Tohru Hashida (Kobe City Medical Center General Hospital / Faculty of Pharmaceutical Sciences, Kobe Gakuin University)  
**薬剤師が取り組むタスク・シフト / シェア**  
橋田 亨 (神戸市立医療センター中央市民病院 / 神戸学院大学薬学部)

SY16-3 **Discuss task sharing/shifting in cancer care from the perspective of nurses**  
Akiyo Kizawa (Japanese Nursing Association)  
**多職種で考えるがん領域のタスクシフティング / シェアリング 看護師の立場から**  
木澤 晃代 (公益社団法人 日本看護協会)

SY16-4 **Discuss task sharing / shifting in cancer care- Point of view from Ministry of Health, Labour and Welfare -**  
Akihiro Manaka (General Affairs Division, Health Policy Bureau, Ministry of Health, Labour and Welfare)  
**多職種で考えるがん領域のタスクシェアリング / タスクシフティング—行政の立場から—**  
真中 章弘 (厚生労働省医政局総務課)

SY16-5 **Task sharing/shifting from the perspective of a lawyer**  
Hidenori Akabane (Chugaigodo Law Offices)  
**法律家からみたタスクシェアリング / タスクシフティング**  
赤羽根 秀宜 (中外合同法律事務所 薬事・ヘルスケア・医療グループ)

第6会場(国立京都国際会館 1階 Room D)

8:20-9:50 Oral Session 9

09 Genitourinary Cancer  
泌尿器

E

Chairs : Keita Uchino (Department of Medical Oncology, NTT Medical Center Tokyo)  
Nobuaki Matsubara (Department of Medical Oncology, National Cancer Center Hospital East)  
Discussant: Ken-ichi Tabata (Department of Urology, Kitasato University School of Medicine)  
司会 : 内野 慶太 (NTT東日本関東病院 腫瘍内科)  
松原 伸晃 (国立がん研究センター東病院 腫瘍内科)  
ディスカッサント: 田畑 健一 (北里大学 泌尿器科)

09-1 Updated analysis of circulating tumor DNA in advanced genitourinary cancers: SCRUM-Japan MONSTAR SCREEN Project

Norio Nonomura (Department of Urology, Osaka University Graduate School of Medicine)

SCRUM-Japan MONSTAR SCREEN基盤を活用した泌尿器がんにおける血中循環腫瘍DNAの網羅的解析

野々村 祝夫 (大阪大学大学院医学系研究科泌尿器科)

09-2 Prognostic role of Vascular Endothelial Growth Factor and Vascular Cell Adhesion Molecule-1 in bladder carcinoma

Keiichiro Mori (Department of Urology, The Jikei University School of Medicine)

森 啓一郎 (東京慈恵会医科大学 泌尿器科)

09-3 SNHG16 mediate cisplatin and gemcitabine resistance in upper tract urothelial carcinoma cells by sponging of miR-31-5p

Wei-Chi Hsu (Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University / Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University / Department of Urology, Kaohsiung Medical University Hospital)

09-4 Upfront abiraterone acetate for high-risk metastatic hormone-sensitive prostate cancer

Kazutoshi Fujita (Department of Urology, Kindai University Faculty of Medicine)

藤田 和利 (近畿大学医学部 泌尿器科)

09-5 Enzalutamide versus abiraterone as a first-line endocrine therapy for CRPC: ENABLE study for PCa

Kouji Izumi (Department of Urology and Integrative Cancer Therapy, Kanazawa University)

去勢抵抗性前立腺癌に対するエンザルタミドとアピラテロンの有効性に関する多施設共同前向きランダム化比較試験(ENABLE study for PCa)

泉 浩二 (金沢大学附属病院 泌尿器科)

09-6 演題取下



O10

Cross-sectional Program  
臓器横断プログラム

E

Chairs : Maki Tanioka (Clinical AI, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University)  
Yoichi Naito (Department of General Internal Medicine/Experimental Therapeutics/Medical Oncology, National Cancer Center Hospital East)

Discussant : Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)

司会 : 谷岡 真樹 (岡山大学医歯薬学域医療AI)  
内藤 陽一 (国立がん研究センター東病院 総合内科/先端医療科/腫瘍内科)

ディスカッサント: 久保木 恭利 (国立がん研究センター東病院 先端医療科)

O10-1

Encore

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

NTRK融合遺伝子陽性の成人患者におけるラロトレクチニブの有効性と安全性

田原 信 (国立がん研究センター東病院 頭頸部内科)

O10-2

Encore

First-in-Human DuoBody® -CD40x4-1BB (GEN1042) Trial: Safety and Initial Clinical Activity in Advanced Solid Tumors

Melissa Johnson (Sarah Cannon Research Institute, Nashville, TN, USA)

O10-3

Neoadjuvant vaccination with GBM6-AD, lysate of glioblastoma stem cell line, induces T-cell response in low-grade glioma

Hirokazu Ogino (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University / Department of Neurological Surgery, University of California, San Francisco)

荻野 広和 (徳島大学大学院医歯薬学研究部 呼吸器・膠原病内科学分野/Department of Neurological Surgery, University of California, San Francisco)

O10-4

The Prediction of the Presence of ALK Fusion Gene in non-small cell lung cancer using Deep Learning platform

Hiroaki Kodama (Division of Thoracic Oncology, Shizuoka Cancer Center)

児玉 裕章 (静岡県立静岡がんセンター 呼吸器内科)

O10-5

BAP1 cancer syndrome

Yasutaka Takinishi (Thoracic Oncology, University of Hawaii Cancer Center)

O10-6

A Prospective Study of Biomarkers and Risk Scores for predicting Venous Thromboembolism in Patients with Advanced Cancer

Yohei Harada (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)

日本人の進行癌患者における静脈血栓塞栓症予測のための血液バイオマーカーおよびリスクスコアに関する前向き観察研究

原田 陽平 (佐賀大学医学部 血液・呼吸器・腫瘍内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

14:05-14:55 Mini-Oral Session 23

**MO23** Hepatobiliary / Pancreatic Cancer 4 (Gallbladder and Biliary Tract Cancer, Miscellaneous) **E**  
 肝胆膵4 (胆嚢・胆道 その他)

Chairs : Satoshi Kobayashi (Department of Gastroenterology, Kanagawa Cancer Center)  
 Satoshi Shimizu (Department of Gastroenterology, Saitama Cancer Center)

司会 : 小林 智 (神奈川県立がんセンター 消化器内科肝胆膵)  
 清水 怜 (埼玉県立がんセンター 消化器内科)

**MO23-1** **Clinical impacts of comprehensive genomic profiling on therapeutic strategies in patients with biliary tract cancer**

Kohichi Takada (Department of Medical Oncology, Sapporo Medical University School of Medicine)

高田 弘一 (札幌医科大学附属病院 腫瘍内科)

**MO23-2** **Characteristics, treatment patterns, and healthcare costs of advanced/metastatic biliary tract cancer patients in Japan**

Seok-Won Kim (IQVIA, Tokyo, Japan)

**MO23-3** **Benefit of Second-line Chemotherapy in Patients with Advanced Biliary Tract Cancer : A Propensity Score analysis**

Kijjakom Thanasombunskh (Department of Internal Medicine, Lampang Hospital, Ministry of Public Health / Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University)

**MO23-4** **Clinical significance of venous thromboembolism in patients with advanced cholangiocarcinoma**

**Encore**

Joo Seong Kim (Department of Internal Medicine, Seoul National University Hospital)

**MO23-5** **Efficacy of radiofrequency ablation after occlusion of self-expandable metal stent in malignant biliary obstruction**

**Encore**

Namyong Park (Department of Medicine, Seoul National University Hospital)

**MO23-6** **A single-center experience of comprehensive genomic profiling of hepatobiliary and pancreatic cancers**

Hiroki Eguchi (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)

江口 大樹 (国立がん研究センター東病院 肝胆膵内科)

15:05-16:35 Symposium 17 / シンポジウム 17

**SY17** Optimal treatment strategy for locally advanced head and neck cancer **E**  
 局所進行頭頸部がんに対する最適な治療戦略

Chairs : Kaoru Tanaka (Department of Medical Oncology, Kindai University Faculty of Medicine)  
 Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

司会 : 田中 薫 (近畿大学医学部附属病院 腫瘍内科)  
 田原 信 (国立がん研究センター東病院 頭頸部内科)

**SY17-1** **Postoperative chemoradiotherapy for head and neck squamous cell carcinoma**

Yoshitaka Honma (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

**頭頸部扁平上皮癌に対する術後化学放射線療法**

本間 義崇 (国立がん研究センター中央病院 頭頸部・食道内科)

- SY17-2 **Induction chemotherapy for head and neck cancer**  
Tomohiro Enokida (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)  
**頭頸部癌における導入化学療法**  
榎田 智弘 (国立がん研究センター東病院 頭頸部内科)
- SY17-3 **Current status and perspective of the combination of immunotherapy and chemoradiotherapy for head and neck cancer**  
Yuji Murakami (Department of Radiation Oncology, Hiroshima University Hospital)  
**頭頸部がんに対する免疫療法と化学放射線療法併用の現状と展望**  
村上 祐司 (広島大学病院 放射線治療科)
- SY17-4 **Optimal treatment strategy for locally advanced nasopharyngeal cancer from the perspectives of Asian endemic region**  
Anthony T.C. Chan (Department of Clinical Oncology, The Chinese University of Hong Kong / Sir Y K Pao Centre for Cancer, The Chinese University of Hong Kong / Hong Kong Cancer Institute, The Chinese University of Hong Kong)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**第7会場 (国立京都国際会館 1階 Room E)**

8:20-9:50 JSMO Membership Committee Program・Career Empowerment Committee Program/  
日本臨床腫瘍学会会員委員会・キャリアエンパワーメント委員会合同企画

**MC** Investigation of the effects of COVID-19 on chemotherapy for malignancies and its future perspective・  
Discuss the Need for Career Counseling!  
COVID-19によるがん薬物療法の影響調査と今後の展開・キャリア相談に関するニーズについてディスカッションする!

**MC-1 COVID-19によるがん薬物療法の影響調査と今後の展開**  
Kei Muro (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
室 圭 (愛知県がんセンター 薬物療法部/日本臨床腫瘍学会 会員委員会委員長)

**MC-2 キャリア相談に関するニーズについてディスカッションする!**

Chairs : Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)  
Mariko Miyagi (Career Psychology Institute)

Discussant : Ikuko Takahashi (Human Resources Department, Taiho Pharmaceutical Co., Ltd.)  
Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)  
Yuka Kobayashi (Department of Gastroenterology and Medical Oncology, Nagaoka Chuo General Hospital)  
Hirohichi Nakazima (Department of Experimental Therapeutics/Department of Medical Oncology, National Cancer Center Hospital East)  
Chikako Iwai (The School of Public Health, Graduate School of Medicine, The University of Tokyo)  
Yoichi Osato (Department of International Clinical Development, National Cancer Center Hospital)  
Nami Sasamoto (Department of Nursing, Kawasaki Medical School General Medical Center)  
Kaori Sugano (Continuing Education, Japanese Nursing Association Kobe Continuing Education Center)

司会 : 中島 貴子 (京都大学大学院医学研究科 早期医療開発学)  
宮城 まり子 (キャリア心理学研究所)  
ディスカッサント: 高橋 郁子 (大鵬薬品工業株式会社)  
下村 昭彦 (国立研究開発法人 国立国際医療研究センター 乳腺・腫瘍内科)  
小林 由夏 (長岡中央総合病院 消化器内科・腫瘍内科)  
中島 裕理 (国立研究開発法人 国立がん研究センター東病院 先端医療科/腫瘍内科)  
祝 千佳子 (東京大学 大学院医学系研究科公共健康医学専攻)  
大里 洋一 (国立研究開発法人 国立がん研究センター中央病院 国際開発部門国際教育室)  
笹本 奈美 (川崎医科大学総合医療センター 看護部)  
菅野 かおり (公益社団法人 日本看護協会 神戸研修センター 教育研修部 認定看護師教育課程)

14:05-14:55 Mini-Oral Session 24

**MO24 Genitourinary Cancer 泌尿器**

Chairs : Aiko Maejima (Department of Urology, National Cancer Center Hospital)  
Yuji Miura (Department of Medical Oncology, Toranomon Hospital)  
司会 : 前嶋 愛子 (国立がん研究センター中央病院 泌尿器・後腹膜腫瘍科)  
三浦 裕司 (虎の門病院 臨床腫瘍科)

**MO24-1 Comparison of Nivo-Ipi versus TKIs as first line therapy for mRCC : Real-world data from multicenter retrospective study**  
Noriyoshi Miura (Department of Urology, Ehime University Graduate School of Medicine)  
三浦 徳宣 (愛媛大学大学院医学系研究科)

- MO24-2 **Clinical Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma**  
Taigo Kato (Department of Urology, Osaka University Graduate School of Medicine)  
**免疫チェックポイント阻害剤治療後に病勢進行した転移性腎細胞がん患者におけるチロシンキナーゼ阻害剤の臨床効果に関する検討**  
加藤 大悟 (大阪大学大学院医学系研究科泌尿器科)
- MO24-3 **Programmed cell death 1 versus programmed cell death ligand 1 inhibitors for renal cell carcinoma: meta-analysis**  
Keiichiro Mori (Department of Urology, The Jikei University School of Medicine)  
森 啓一郎 (東京慈恵会医科大学 泌尿器科)
- MO24-4 **演題取下**
- MO24-5 **Everolimus in angiomylioma of tuberous sclerosis-A ten years follow-up case report**  
Devashish Kaushal (Department of Urology, All India Institute of Medical Sciences Bhopal (MP) India)
- MO24-6 **The Incidence, Mortality and Clinical Characteristic of Metastatic Hormone-Sensitive Prostate Cancer in Asian population**  
Tanasarit Thepsartra (Department of Medical Oncology, Ramathibodi Hospital, Mahidol University)

15:05-16:35 Symposium 18 / シンポジウム 18

**SY18 PARP inhibitor for Ovarian Cancer Treatment**



Chairs : Keiichi Fujiwara (Department of Gynecologic Oncology, Saitama Medical University)  
Mansoor Raza Mirza (Department of Oncology, The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital)

司会 : 藤原 恵一 (埼玉医科大学国際医療センター 婦人科腫瘍科)  
Mansoor Raza Mirza (The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital)

- SY18-1 **Niraparib for ovarian cancer**  
Mansoor Raza Mirza (The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital)
- SY18-2 **PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations**  
Isabelle Ray-Coquard (Department of Medical Oncology, University Claude Bernard Lyon1-Centre Léon Bérard)
- SY18-3 **Mechanisms of acquired resistance to platinum compounds and PARP inhibitors in BRCA1/2-mutated cancer cells**  
Toshiyasu Taniguchi (Department of Molecular Life Science, Tokai University School of Medicine)  
**BRCA1・BRCA2変異腫瘍におけるPARP阻害薬・Platinum抵抗性獲得のメカニズム**  
谷口 俊恭 (東海大学医学部医学科基礎医学系 分子生命科学)
- SY18-4 **The reason why platinum sensitivity is used for a clinical biomarker of PARP inhibitor sensitivity may be explained by the Schlafen 11 (SLFN11)**  
Junko Murai (Institute for Advanced Biosciences, Keio University)  
**プラチナ製剤感受性がPARP阻害剤感受性の臨床バイオマーカーとして使える理由はSLFN 11で説明できるかもしれない**  
村井 純子 (慶應義塾大学先端生命科学研究所)

## 第8会場 (国立京都国際会館 1階 さくら)

8:20-9:50 Presidential Symposium 6 / 会長企画シンポジウム 6

**PSY6** UPDATE on Cancer of Unknown Primary  
原発不明がんUPDATE



Chairs : Yuichi Takiguchi (Department of Medical Oncology, Chiba University)  
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University, Faculty of Medicine)  
司会 : 滝口 裕一 (千葉大学医学部附属病院 腫瘍内科)  
林 秀敏 (近畿大学 内科学 腫瘍内科)

**PSY6-1 Therapeutic strategy of immune checkpoint inhibitors for cancer of unknown primary (CUP)**

Junko Tanizaki (Department of Medical Oncology, Kindai University Faculty of Medicine)

**原発不明癌に対する免疫チェックポイント阻害薬の治療戦略**

谷崎 潤子 (近畿大学医学部内科学教室 腫瘍内科部門)

**PSY6-2 Site-specific medication therapy based on the predicted primary-site by IHC for unfavourable subset of cancer of unknown primary**

Masashi Ando (Department of Clinical Oncology, Aichi Cancer Center)

**原発不明癌予後不良群に対する免疫組織化学検査により推定された原発巣に準じた薬物療法の治療成績**

安藤 正志 (愛知県がんセンター 薬物療法部)

**PSY6-3 Site-prediction based on molecular profiling for CUP. Is this needed?**

Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)

**原発不明がんに対する分子学的プロファイルからの原発巣推定治療戦略、原発巣推定は必要?**

林 秀敏 (近畿大学病院 腫瘍内科)

**PSY6-4 Diagnosis and Treatment for Rare Cancers of Unknown Primary**

Emi Noguchi (Department of Medical Oncology, National Cancer Center Hospital)

**原発不明な希少がん(例; アポクリン腺がん、乳房外Paget病、NUTなど)に対する治療選択**

野口 瑛美 (国立がん研究センター中央病院 腫瘍内科)

9:50-11:20 Asia-Pacific/JSMO Joint Symposium / Asia-Pacific/JSMO 合同シンポジウム

**APJS Pan-Asian Clinical Trial**



Chairs : Kan Yonemori (Department of Medical Oncology, National Cancer Center Hospital, Tokyo)  
Tetsuya Mitsudomi (Department of Thoracic Surgery, Kindai University)  
司会 : 米盛 勲 (国立がん研究センター中央病院 腫瘍内科)  
光富 徹哉 (近畿大学 医学部呼吸器外科)

**APJS-1 International trial activity of AGITG**

Timothy J Price (Department of Medical Oncology, The Queen Elizabeth Hospital)

**APJS-2 Pan-Asian Clinical Trial**

Keunchil Park (Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)

**APJS-3 Current status and future perspectives of ATLAS project**

Kenichi Nakamura (Department of International Clinical Development, National Cancer Center Hospital)

**アジア地域での臨床試験ネットワーク構築の試み(ATLASプロジェクト)**

中村 健一 (国立がん研究センター中央病院 国際開発部門)

APJS-4 Masahiro Tsuboi (Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East)  
坪井 正博 (国立がん研究センター東病院 呼吸器外科)

14:05-14:45 Mini-Oral Session 25

**MO25** Translational Research / Clinical Pharmacology 4 (Miscellaneous)  
TR・臨床薬理4 (その他)

E

Chairs : Chiyo K. Imamura (Advanced Cancer Translational Research Institute, Showa University)  
Yoshitsugu Horio (Department of Outpatient Services, Aichi Cancer Center Hospital)  
司会 : 今村 知世 (昭和大学 先端がん治療研究所)  
堀尾 芳嗣 (愛知県がんセンター 外来部)

**MO25-1** Prognostic values of SII index and systemic inflammatory markers in advanced cancer received palliative chemotherapy

Chanchai Charonpongsuntorn (Medical Oncology Unit, Department of Internal Medicine, Srinakharinwirot University)

**MO25-2** Phase I study of tiragolumab in combination with atezolizumab in Japanese patients with advanced solid tumors

Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)  
山本 昇 (国立がん研究センター中央病院 先端医療科)

**MO25-3** Regorafenib-induced erythema multiforme is associated with *HLA-C\*01:02* and *HLA-B\*46:01* in Japanese cancer patients

Natsumi Matsumoto (Division of Cancer Genome and Pharmacotherapy, Showa University School of Pharmacy)  
松本 奈都美 (昭和大学薬学部臨床薬学講座がんゲノム医療薬学部門)

**MO25-4** Exploratory Analysis of HER2 Extracellular Domain in HER2 Positive Gastric Cancer treated with SOX plus Trastuzumab

Shuichi Hironaka (Clinical Trial Promotion Department, Chiba Cancer Center)  
廣中 秀一 (千葉県がんセンター 臨床試験推進部)

**MO25-5** A Phase 1 Study to Compare Formulations and Evaluate the Effect of Food on Pimitepsib in Patients with Solid Tumors

Kazuo Kasahara (Department of Respiratory Medicine, Kanazawa University Hospital)  
固形がん患者を対象とするピミテスピブの製剤比較及び食事の影響を評価する第1相試験  
笠原 寿郎 (金沢大学附属病院 呼吸器内科)

15:05-16:35 Symposium 19 / シンポジウム 19

**SY19** Cutting edge of treatment for colorectal cancer -current status and future perspective  
標的分子からみた大腸癌治療の現状と展望

E

Chairs : Eric Van Cutsem (University Hospitals Gasthuisberg / Leuven & KU Leuven)  
Kei Muro (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
司会 : Eric Van Cutsem (University Hospitals Gasthuisberg / Leuven & KU Leuven)  
室 圭 (愛知県がんセンター 薬物療法部)

**SY19-1** Cutting-edge of treatment strategy for colorectal cancer with molecular and genetic abnormalities

Eric Van Cutsem (Digestive Oncology, University of Leuven, Belgium)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu)		
Day 2 (Fri)	SY19-2	<b>Biomarker-guided therapy for colorectal cancer; molecular biological perspectives</b> Hiroya Taniguchi (Department of Clinical Oncology, Aichi Cancer Center Hospital) <b>大腸癌における標的治療；分子生物学的な視点から</b> 谷口 浩也 (愛知県がんセンター 薬物療法部)
Day 3 (Sat)	SY19-3	<b>New era of colorectal cancer treatment -Asian perspective</b> Tae Won Kim (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Room 1	SY19-4	<b>Precision oncology for adjuvant treatment of colon cancer</b> Eiji Oki (Department of Surgery and Science, Kyushu University) <b>結腸癌補助療法におけるPrecision oncology</b> 沖 英次 (九州大学大学院 消化器・総合外科)
Room 2		
Room 3	SY19-5	<b>Future perspective for the targeted/personalized therapy of mCRC</b> Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East) <b>大腸がんにおける標的治療の将来展望</b> 久保木 恭利 (国立がん研究センター東病院 先端医療科)
Room 4		
Room 5		
Room 6		
Room 7		
Room 8		
Room 9		
Room 10		
Room 11		
Room 12		
Room 13		
Meet the Experts		
Poster		



## 第9会場 (国立京都国際会館 1階 スワン)

8:20-9:40 Oral Session 11

### O11 Multidisciplinary Team Program 多職種連携プログラム

Chairs : Tomi Tanaka (School of Medicine Faculty of Nursing, Nara Medical University)  
Mihoko Doi (Department of Clinical Oncology, Hiroshima Prefectural Hospital)  
Discussant: Takuro Sakurai (Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital)  
司会 : 田中 登美 (奈良県立医科大学医学部看護学科/成人慢性期看護学)  
土井 美帆子 (県立広島病院 臨床腫瘍科)  
ディスカッサント: 櫻井 卓郎 (国立がん研究センター中央病院 骨軟部腫瘍・リハビリテーション科)

#### 011-1 Prognostic impacts of loss of skeletal muscle mass during neoadjuvant chemotherapy in older esophageal cancer patients

Tsuyoshi Harada (Department of Rehabilitation, National Cancer Center Hospital East, Chiba, Japan / Department of Rehabilitation Medicine, Keio University Graduate School, Tokyo, Japan)

##### 術前補助化学療法中の骨格筋量減少が高齢食道癌患者の予後に及ぼす影響

原田 剛志 (国立がん研究センター東病院 リハビリテーション科/慶應義塾大学大学院 医学研究科 リハビリテーション医学教室)

#### 011-2 The correlation between the efficacy of rehabilitation and nutritional condition in cancer patients.

Takashi Imajima (Sasebo Kyosai Hospital)

##### がんリハビリテーションの有効性および栄養状態が与える影響

今嶋 克志 (佐世保共済病院)

#### 011-3 Usefulness of the MEWS as an ultra-short-term prognosis predictor for patients with gastrointestinal cancer

Tomomi Sanomachi (Dept. Clin. Oncol., Japan. Red Cross Ishinomaki Hosp. / Dept. Clin. Oncol., Yamagata Univ. Hosp.)

消化器系統癌患者における超短期予後予測指標としての修正早期警告スコアの有用性の検討  
佐野町 友美 (石巻赤十字病院/山形大学医学部附属病院腫瘍内科)

#### 011-4 Changes in body composition and quality of life due to perioperative chemotherapy for early breast cancer

Mihoko Doi (Department of Clinical Oncology, Hiroshima Prefectural Hospital)

##### 周術期乳がん化学療法による体組成、QOLの変化についての検討

土井 美帆子 (県立広島病院 臨床腫瘍科)

#### 011-5 Relationship between febrile neutropenia and oral bacteria in breast cancer chemotherapy

Shinsuke Sasada (Department of Breast Surgery, Hiroshima University Hospital)

##### 乳癌化学療法における発熱性好中球減少症と口腔内細菌数の関連

笹田 伸介 (広島大学病院 乳腺外科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the Experts  
 Poster

10:00-10:50 Mini-Oral Session 26

**MO26** Head and Neck Cancer 1 (Clinical Practice & Basic Practice)  
 頭頸部1(臨床・基礎)



Chairs : Shigenori Kadowaki (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
 Yoshitaka Honma (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

司会 : 門脇 重憲 (愛知県がんセンター 薬物療法部)  
 本間 義崇 (国立がん研究センター中央病院 頭頸部・食道内科)

**MO26-1 miR-21 and miR-184 as early diagnostic miRs for oral squamous cell carcinomas and oral potentially malignant disorders**

Aarushi Garg (Department of oral pathology and microbiology, Maulana Azad Institute of Dental Sciences)

**MO26-2 Intra-tumoral clusters between CD20+ B cells and BCL6+ CD4+ T cells are prognostic in early oral cancers**

Chumut Phathunane (Department of Medical Oncology, HRH Princess Chulabhorn College of Medical Science / Departments of Otorhinolaryngology, Erasmus MC Cancer Institute)

**MO26-3 miR-155-5p and miR-1246 as promising biomarkers in oral squamous cell carcinomas**

Maheswari Ramamoorthy (Department of Oral Pathology, Maulana Azad Institute of Dental Sciences, New Delhi 110002, India)

**MO26-4 The relationship between PD-L1 expression and therapeutic effect of anti-PD-1 antibody in head and neck cancers**

Akihiro Ohara (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

大原 章裕 (国立がん研究センター中央病院 頭頸部・食道内科)

**MO26-5 Retrospective Analysis of Pembrolizumab Alone or with Chemotherapy for Recurrent or Metastatic Head and Neck Cancer**

Jun Taguchi (Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University)

田口 純 (北海道大学大学院医学研究院腫瘍内科学教室)

**MO26-6 Short-term outcomes of induction chemotherapy followed by chemoradiotherapy in locally advanced sinonasal carcinoma**

Mai Itoyama (Department of Head&Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

伊東山 舞 (国立がん研究センター中央病院 頭頸部・食道内科)

**MO27** Head and Neck Cancer 2 (Clinical Practice)  
頭頸部2 (臨床)

Chairs : Yoshinori Imamura (Department of Medical Oncology and Hematology, Kobe University Hospital)  
Susumu Okano (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

司会 : 今村 善宣 (神戸大学大学院医学研究科 腫瘍・血液内科学)  
岡野 晋 (国立がん研究センター東病院 頭頸部内科)

**MO27-1** Weekly versus Three-Weekly Cisplatin Administration in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

Ramon Jr B. Larrazabal (Division of Medical Oncology, Department of Medicine, Philippine General Hospital)

**MO27-2** Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer

Ari Nishimura (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
西村 在 (静岡県立静岡がんセンター 消化器内科)

**MO27-3** The mGPS is a potential predictor for early recurrences in patients with HNSCC who underwent chemoradiotherapy

Shohei Udagawa (Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.)  
宇田川 翔平 (がん研究会有明病院 総合腫瘍科)

**MO27-4** Chemoembolization with followed radiation therapy in patients with locally advanced nasopharyngeal carcinoma**Encore**

Alexander S Mitrofanov (NMRC of Oncology named after N.N.Petrov of MoH of Russia)

**MO27-5** Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma: a retrospective study

Hiroyuki Kodama (Department of clinical oncology, Aichi Cancer Center Hospital)  
児玉 紘幸 (愛知県がんセンター 薬物療法部)

**MO27-6** When should we start sorafenib or lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma?

Yasuhiro Ito (Department of Clinical Trial, Kuma Hospital / Department of Surgery, Kuma Hospital)  
伊藤 康弘 (隈病院治験臨床試験管理科 / 隈病院外科)

## 第10会場 (ザ・プリンス 京都宝ヶ池 1階 ロイヤルルーム)

8:20-9:00 JSMO Committee on Guideline Program / 日本臨床腫瘍学会 ガイドライン委員会企画

**GL1** Outline of the Clinical Practice Guidelines for Tumor-Agnostic Treatments in Adult and Pediatric Patients with Advanced Solid Tumors toward Precision Medicine (3rd Edition)  
成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン(第3版)の概要

Chairs : Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
Eishi Baba (Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)

司会 : 吉野 孝之 (国立がん研究センター東病院 消化管内科)  
馬場 英司 (九州大学大学院 医学研究院 社会環境医学講座 連携社会医学分野)

**GL1-1** Clinical Practice Guideline for tumor-agnostic treatment in patients with advanced solid tumors focus on DNA mismatch repair and tumor mutation burden

Saori Mishima (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

**固形がんにおけるミスマッチ修復機能(mismatch repair; MMR)と腫瘍遺伝子変異量(tumor mutation burden; TMB)のガイドライン**

三島 沙織 (国立がん研究センター東病院 消化管内科)

**GL1-2** Clinical Practice Guidelines for Tumor-Agnostic Treatments in Adult and Pediatric Patients with Advanced Solid Tumors: NTRF fusion/other biomarkers

Yoichi Naito (Department of General Internal Medicine, National Cancer Center Hospital East)

**成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン: NTRK融合遺伝子、その他のバイオマーカー**

内藤 陽一 (国立がん研究センター東病院 総合内科)

9:10-9:50 JSMO Committee on Guideline Program / 日本臨床腫瘍学会 ガイドライン委員会企画

**GL2** About the Practical Guideline of Bone Metastasis, Revised 2nd Edition  
骨転移診療ガイドライン改訂第2版について

Chair : Hiroyuki Shibata (Department of Clinical Oncology, Graduate School of Medicine, Akita University)

司会 : 柴田 浩行 (秋田大学大学院医学系研究科 臨床腫瘍学分野)

**GL2-1** Diagnosis of bone metastasis, local treatment (other than surgery)

Shunsuke Kato (Department of Clinical Oncology, Juntendo University Graduate School of Medicine)

**骨転移の診断、手術を除く局所治療**

加藤 俊介 (順天堂大学大学院医学研究科 臨床腫瘍学)

**GL2-2** Importance of locomotive management -Significance of ambulant ability in patients with bone metastasis-

Hiroataka Kawano (Department of Orthopaedic Surgery, Teikyo University School of Medicine)

**運動器管理の重要性 -骨転移患者が歩けることの意義-**

河野 博隆 (帝京大学 整形外科)

**GL2-3** Efficacy of bone modifying agents and anticancer drugs

Hisakazu Nishimori (Department of Hematology and Oncology, Okayama University Hospital)

**骨修飾薬とがん薬物療法の有効性**

西森 久和 (岡山大学病院 血液・腫瘍内科)

- GL2-4 **Safe and effective use of Bone modifying agent**  
Makoto Kodaira (Department of Medical Oncology, Kodaira Hospital)  
**Bone modifying agentの安全かつ効果的な使用**  
公平 誠 (公平病院 腫瘍内科)
- GL2-5 **Criteria for treatment efficacy, analgesics, RI therapy, rehabilitation, and nursing**  
Ikuro Sekine (Department of Medical Oncology, University of Tsukuba)  
**治療効果判定基準、鎮痛薬、RI療法、リハビリと看護**  
関根 郁夫 (筑波大学 医学医療系 臨床腫瘍学)
- 14:05-15:25 Oral Session 12
- O12** Rare Cancer / Cancer of Unknown Primary  
希少がん・原発不明がん **E**
- Chairs : Yusuke Onozawa (Division of Clinical Oncology, Shizuoka Cancer Center)  
Junichi Tomomatsu (Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
- Discussant : Shu Yazaki (Department of Medical Oncology, National Cancer Center Hospital)
- 司会 : 小野澤 祐輔 (静岡県立静岡がんセンター 原発不明科)  
友松 純一 (がん研究会 有明病院 総合腫瘍科)
- ディスカッサント: 矢崎 秀 (国立がん研究センター中央病院 腫瘍内科)
- O12-1 **Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G)**  
Yuki Matsubara (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
松原 裕樹 (愛知県がんセンター 薬物療法部)
- O12-2 **The epidemiology of rare cancers from National Cancer Registry in Japan**  
Tomoyuki Satake (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)  
佐竹 智行 (国立がん研究センター中央病院 肝胆膵内科)
- O12-3 **Comprehensive significance of cancer genomic profiling (CGP) tests in patients with advanced skin cancers**  
Dai Ogata (Department of dermatologic oncology, National Cancer Center Hospital)  
緒方 大 (国立がん研究センター中央病院 皮膚腫瘍科)
- O12-4 **Clinical significance of comprehensive genomic profiling in pediatric cancer patients**  
Minako Sugiyama (Division of Clinical Cancer Genomics, Hokkaido University Hospital / Department of Pediatrics, Hokkaido University Hospital)  
杉山 未奈子 (北海道大学病院/北海道大学病院小児科)
- O12-5 **A retrospective analysis of the clinical factor affecting the prognosis of non-seminomatous mediastinal germ cell tumor**  
Yosuke Amano (Department of Medical Oncology, National Cancer Center Hospital)  
**当院における縦隔非セミノーマ胚細胞腫瘍の予後予測因子の後ろ向き解析**  
天野 陽介 (国立がん研究センター中央病院 腫瘍内科)

15:30-16:20 Mini-Oral Session 28

**MO28** Rare Cancer / Cancer of Unknown Primary 2 (Miscellaneous)  
希少がん・原発不明がん2(その他)

**E**

Chairs : Ken-ichi Ito (Division of Breast & Endocrine Surgery, Department of Surgery, Shinshu University)  
Kazuhiko Sugiyama (Department of Clinical Oncology & Neuro-Oncology Program, Hiroshima University Hospital)

司会 : 伊藤 研一 (信州大学医学部 外科学教室 乳腺内分泌外科学分野)  
杉山 一彦 (広島大学病院 がん化学療法科)

**MO28-1 Prognostic factors for the central nervous system germinoma**  
Fumiyuki Yamasaki (Department of Neurosurgery, Hiroshima University Hospital)

**Germinomaの長期予後因子**  
山崎 文之 (広島大学病院 脳神経外科)

**MO28-2 Extraocular Retinoblastoma: Fight against an ocular malignancy outside the eye.**  
Ahmed Elhusssein Abdelsalam (Department of Pediatric Hematology/Oncology, Children's Cancer Hospital Egypt)

**MO28-3 Efficacy and safety of irinotecan monotherapy and amrubicin monotherapy for platinum-refractory neuroendocrine carcinoma**

Sakura Hiraide (Department of Medical Oncology, Tohoku University Hospital)  
**白金製剤抵抗性の進行神経内分泌癌に対するイリノテカン単剤療法とアムルビシン単剤療法の有効性と安全性の後方視的解析**  
平出 桜 (東北大学病院 腫瘍内科)

**MO28-4 Diagnostic Accuracy of 18F-FDG PET-CT in Detection of Primary Tumor in Patients with Bone Metastasis of Unknown Origin**

Naila Sheikh (Department of PET CT and Nuclear Medicine, Institute of Nuclear Medicine and Oncology Lahore)

**MO28-5 Clinical utility of comprehensive genomic profiling for patients with cancer of unknown primary site**

Ryo Kudo (Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University)

**原発不明癌に対するCGP検査の有用性について**  
工藤 亮 (東京医科歯科大学病院 がんゲノム診療科)

**MO28-6 A retrospective analysis of cancer multigene panel testing for thyroid cancer at our hospital**

Tokiko Ito (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University school of Medicine)

**当院での甲状腺癌に対するがん遺伝子パネル検査施行症例の検討**  
伊藤 勲子 (信州大学医学部外科学教室 乳腺内分泌外科学分野)

## 第11+12会場 (ザ・プリンス 京都宝ヶ池 B2階 プリンスホール1+2)

8:20-9:50 Symposium 20 / シンポジウム 20

**SY20** Development of treatment for patients with non-small cell lung cancer harboring rare driver mutations  
比較的稀なドライバー遺伝子変異陽性肺癌に対する治療開発

E

Chairs : Hye Ryun Kim (Yonsei Cancer Center)  
Takehito Shukuya (Respiratory Medicine, Juntendo University)  
司会 : Hye Ryun Kim (Yonsei Cancer Center)  
宿谷 威仁 (順天堂大学 呼吸器内科)

SY20-1 **Novel Agents for KRAS mutant NSCLC**  
Pasi A. Janne (Dana Farber Cancer Institute)

SY20-2 **New treatment options for RET fusion positive NSCLC**  
Benjamin J. Solomon (Department of Medical Oncology, Peter MacCallum Cancer Centre)

SY20-3 **Development of treatment for HER2 or EGFR Exon 20 insertion mutation-driven NSCLC**  
Kiichiro Ninomiya (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

**HER2遺伝子異常陽性、EGFR exon20遺伝子変異陽性肺癌に対する治療開発**  
二宮 貴一朗 (岡山大学学術研究院医歯薬学域 血液・腫瘍・呼吸器内科学)

SY20-4 **Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data**  
Toshio Fujino (Department of Surgery, Division of Thoracic Surgery, Kindai University Faculty of Medicine)

**MET, NTRK, BRAF遺伝子異常を有する肺癌に対する治療戦略と耐性克服**  
藤野 智大 (近畿大学医学部外科学教室呼吸器外科部門)

9:50-11:20 Symposium 21 / シンポジウム 21

**SY21** RAS/RAF pathway-altered cancers

E

Chairs : Yasuhiro Koh (Center for Biomedical Sciences, Wakayama Medical University)  
Ryan B. Corcoran (Massachusetts General Hospital Cancer Center)  
司会 : 洪 泰浩 (和歌山県立医科大学 バイオメディカルサイエンスセンター)  
Ryan B. Corcoran (Massachusetts General Hospital Cancer Center)

SY21-1 **Overcoming Clinical Resistance to KRAS inhibition**  
Ryan B. Corcoran (Massachusetts General Hospital Cancer Center)

SY21-2 **Drug development targeting RAF/MEK pathway**  
Hisako Ono (Department of Medical Oncology, Japanese Red Cross Kyoto Daini Hospital /  
Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine)

**RAF/MEK経路を標的とした薬剤の開発**

小野 寿子 (京都第二赤十字病院 腫瘍内科 / 京都府立医科大学 創薬医学)

SY21-3 **RET-altered cancers: toward tumor agnostic therapy**  
Takashi Kohno (Division of Genome Biology, National Cancer Center Research Institute)

**RET遺伝子異常を持つ様々ながんの治療**

河野 隆志 (国立がん研究センター研究所ゲノム生物学研究分野)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

SY21-4 **Mechanisms of resistance to RAS-targeting therapies**  
 Hiromichi Ebi (Division of Molecular Therapeutics, Aichi Cancer Center Research Institute)  
**KRAS阻害薬の耐性機序**  
 衣斐 寛倫 (愛知県がんセンター研究所 がん標的治療トランスレーショナルリサーチ分野)

15:05-16:35 Symposium 22 / シンポジウム 22

**SY22 Future challenge of liquid biopsy for next generation cancer therapeutics** **E**

Chairs : Maki Tanioka (Department of Medical AI, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences)  
 Antoine Italiano (Head of Precision Medicine Program Gustave Roussy Campus, Villejuif, France)  
 司会 : 谷岡 真樹 (岡山大学大学院医歯薬学総合研究科 医療AIコーディネーター)  
 Antoine Italiano (Head of Precision Medicine Program Gustave Roussy Campus, Villejuif, France)

SY22-1 **Assign optimal roles between plasma-derived or tumor-derived gene panel**  
 Koshi Mimori (Department of Surgery, Kyushu University Beppu Hospital)  
**cfDNAパネルと腫瘍遺伝子パネルとの適切な役割分担とは？**  
 三森 功士 (九州大学病院別府病院)

SY22-2 **Clinical relevance of comprehensive genomic profiling for hematologic malignancies**  
 Keisuke Kataoka (Division of Hematology, Department of Medicine, Keio University School of Medicine)  
**造血器腫瘍における網羅的ゲノムプロファイリング検査の臨床的意義**  
 片岡 圭亮 (慶應義塾大学医学部血液内科)

SY22-3 **Implementing ctDNA next-generation sequencing with a large panel in a precision medicine program: clinical impact for patient management**  
 Antoine Italiano (Head of Precision Medicine Program Gustave Roussy Campus, Villejuif, France)

SY22-4 **Current and Future Paradigms of Liquid Biopsy for Cancer Care**  
 Yoshiaki Nakamura (National Cancer Center Hospital East)  
**がん診療におけるリキッドバイオプシーの現状と未来のパラダイム**  
 中村 能章 (国立がん研究センター東病院)



## 第13会場 (ザ・プリンス 京都宝ヶ池 B2階 ゴールドルーム)

8:20-9:50 Symposium 23 / シンポジウム 23

**SY23** Encyclopedic Seamless Drug Development for Organ Agnostic Oncology Precision Medicine - Frontline therapeutics of targeting BRCA(HRD), PARP, HER2 and NTRK genetic alteration - **E**

Chairs : Kenji Tamura (Department of Medical Oncology/Innovative Cancer Center, Shimane University Hospital)  
Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)  
司会 : 田村 研治 (島根大学医学部附属病院 先端がん治療センター/腫瘍内科)  
近藤 千紘 (国立がん研究センター東病院 腫瘍内科)

**SY23-1 Organ-agonistic anti-cancer drug development; HER2 or BRAF targeting**  
Kenji Tamura (Department of Medical Oncology/Innovative Cancer Center, Shimane University Hospital)

**HER2又はBRAFを標的とした臓器横断的な抗悪性腫瘍薬開発**

田村 研治 (島根大学医学部附属病院 先端がん治療センター/腫瘍内科)

**SY23-2 Tumor agnostic drug development targeting BRCA or HRD - breast, pancreatic and prostate cancer**

Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)

**BRCA又はHRDを標的とした臓器横断的薬剤開発－乳がん・膵がん・前立腺がん**

近藤 千紘 (国立がん研究センター東病院 腫瘍内科)

**SY23-3 Clinical Development of PARP Inhibitors in Ovarian Cancer**

Keiichi Fujiwara (Department of Gynecologic Oncology)

**卵巣癌におけるPARP阻害薬の臨床開発**

藤原 恵一 (埼玉医科大学国際医療センター 包括的がんセンター)

**SY23-4 Tumor Agnostic Development, An Industry Perspective**

David Hyman (Department of Loxo Oncology and Lilly Oncology, Loxo Oncology at Eli Lilly)

9:55-10:45 Mini-Oral Session 29

**MO29** Lung Cancer / Thoracic Cancer 4(EGFR-TKI 1)  
呼吸器4(EGFR-TKI 1) **E**

Chairs : Kazuma Kishi (Department of Respiratory Medicine, Toho University)  
Toshiyuki Kozuki (Clinical Research Center, National Hospital Organization Shikoku Cancer Center)

司会 : 岸 一馬 (東邦大学医学部内科学講座呼吸器内科学分野)  
上月 稔幸 (国立病院機構四国がんセンター 臨床研究センター)

**MO29-1 The relationship between EGFR variant allele frequency and efficacy of Osimertinib in EGFR mutation-positive NSCLC**

Seigo Katakura (Department of Thoracic Oncology, Kanagawa Cancer Center)

片倉 誠悟 (神奈川県立がんセンター 呼吸器内科)

**MO29-2 Efficacy of dacomitinib in re-treatment setting for patients with EGFR mutant NSCLC (TOPGAN2020-02)**

Hiroaki Sakamoto (Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research)

坂本 博昭 (がん研究会有明病院呼吸器内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)	MO29-3	<b>A database of 1023 patients with NSCLC and uncommon <i>EGFR</i> mutations treated with afatinib: focus on Asian patients</b> Satoru Miura (Department of Internal Medicine, Niigata Cancer Center Hospital) 三浦 理 (新潟県立がんセンター新潟病院 内科)
Day 2 (Fri)	MO29-4 Encore	<b>Sequential afatinib and osimertinib in Asians with <i>EGFR</i>m+ NSCLC: combined analysis of two non-interventional studies</b> Satoru Miura (Department of Internal Medicine, Niigata Cancer Center Hospital) 三浦 理 (新潟県立がんセンター新潟病院 内科)
Day 3 (Sat)	MO29-5	<b>Updated safety and efficacy of poziotinib in Japanese patients with non-small cell lung cancer: Phase 1 study</b> Akira Ono (Division of Thoracic Oncology, Shizuoka Cancer Center) 小野 哲 (静岡県立静岡がんセンター 呼吸器内科)
Room 1	MO29-6 Encore	<b>Genomic profiles and potential determinants of response and resistance to sotorasib in <i>KRAS</i> p.G12C-mutated NSCLC</b> Toshiaki Takahashi (Division of Thoracic Oncology, Shizuoka Cancer Center) 高橋 利明 (静岡県立静岡がんセンター 呼吸器内科)
Room 2	Room 3	Room 4
Room 5	14:05-15:35	Joint Symposium 3 (JSPM/JSMO) / 合同シンポジウム 3 (日本緩和医療学会/日本臨床腫瘍学会)
Room 6	JS3	<b>Rethinking the Integration of Oncology and Palliative Care</b> あらためて、緩和ケアとオンコロジーのインテグレーションを考える
Room 7	Chairs :	Toshimi Takano (Breast Medical Oncology, The Cancer Institute Hospital of JFCR) Masanori Mori (Palliative and Supportive Care Division, Seirei Mikatahara General Hospital)
Room 8	司会 :	高野 利実 (がん研究会有明病院 乳腺内科) 森 雅紀 (聖隷三方原病院 緩和支援治療科)
Room 9	JS3-1	<b>Oncologists' concerns about symptom relief and timing of transition to home</b> Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East) <b>オンコロジストの悩む症状緩和と在宅移行のタイミング</b> 近藤 千紘 (国立がん研究センター東病院 腫瘍内科)
Room 10	JS3-2	<b>How should oncology and palliative care be integrated?</b> Tomohiro Nishi (Department of Medical Oncology, Kawasaki Municipal Ida Hospital) <b>腫瘍内科と緩和ケアはどのように融合されるべきなのか</b> 西 智弘 (川崎市立井田病院 腫瘍内科)
Room 11	JS3-3	<b>Decision-making support in collaboration with oncologists: From the perspective of nurses</b> Mineko Mukai (Department of Nursing, Aichi Cancer Center Hospital) <b>オンコロジストと協働して行う意思決定支援 ~看護師の立場から~</b> 向井 未年子 (愛知県がんセンター 看護部)
Room 12	JS3-4	<b>Consider the integration of palliative care and oncology</b> Satoru Shimoyama (Department of Palliative Care, Aichi Cancer Center Hospital) <b>緩和ケアと腫瘍学のインテグレーションを再考する</b> 下山 理史 (愛知県がんセンター 緩和ケア部)
Room 13	Meet the Experts	
Poster		

**MO30**Hematologic Malignancies  
血液

Chairs : Takayuki Ikezoe (Department of Hematology, Fukushima Medical University)  
 Tsutomu Sato (Department of Hematology, Toyama University School of Medicine)  
 司会 : 池添 隆之 (福島県立医科大学 血液内科学講座)  
 佐藤 勉 (富山大学学術研究部医学系血液内科学)

**MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients**

Akinao Okamoto (Department of Hematology, Fujita Health University School of Medicine)  
 岡本 晃直 (藤田医科大学 血液内科)

**MO30-2 WT1 mRNA expression level is a potentially useful marker for the monitoring of MRD in pediatric patients with ALL**

Yoshiko Hashii (Department of Pediatrics, Osaka International Cancer Institute / Japan Association of Childhood Leukemia Study)  
 橋井 佳子 (大阪国際がんセンター 小児科/日本小児白血病研究会)

**MO30-3 Clinical characteristics of DLBCL patients experiencing early disease progression among lower IPI risk groups**

Emi Kemmoku (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital)  
 見目 絵光 (愛知県がんセンター 血液・細胞療法部)

**MO30-4 The prognostic impact of body mass index decrease during the first chemotherapy in advanced follicular lymphoma patients**

Makoto Ito (Department of Hematology, Toyota Kosei Hospital)  
 伊藤 真 (豊田厚生病院 血液内科)

**MO30-5 Clinicopathological factors affecting prognosis in marginal zone lymphoma in an Asian tertiary cancer centre**

Yao Neng Teo (Yong Loo Lin School of Medicine, National University of Singapore, Singapore)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**Meet the Experts会場① (国立京都国際会館 2階 Room I)**

8:20-9:20 Meet the Experts 6

**ME06** Developments of novel therapies in Gastrointestinal Stromal Tumor (GIST): Looking towards the future and learning from the past **E**

Chair : Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital)  
司会 : 土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)

**Developments of novel therapies in Gastrointestinal Stromal Tumor (GIST): Looking towards the future and learning from the past**  
Suzanne George (Department of Medical Oncology, Dana-Farber Cancer Institute)

11:20-12:20 Meet the Experts 7

**ME07** New treatment strategy for hepatobiliary cancer **E**

Chairs : Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital)  
Sadahisa Ogasawara (Department of Gastroenterology, Chiba University, Graduate School of Medicine)  
司会 : 寺島 健志 (金沢大学附属病院 消化器内科)  
小笠原 定久 (千葉大学大学院医学研究院 消化器内科学)

**ME07** **New treatment strategy for hepatobiliary cancer**  
Ghassan Abou-Alfa (Memorial Sloan Kettering Cancer Center)

14:05-15:05 Meet the Experts 8

**ME08** Revolutionizing the treatment of small cell lung cancer **E**

Chair : Daichi Fujimoto (Internal medicine 3, Wakayama Medical University)  
司会 : 藤本 大智 (和歌山県立医科大学 内科学第三講座)

**Revolutionizing the treatment of small cell lung cancer**  
Myung-ju Ahn (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)

15:25-16:25 Meet the Experts 9

**ME09** Perspectives for clinical trials in upper GI cancer **E**

Chair : Izuma Nakayama (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)  
司会 : 中山 巖馬 (がん研究会有明病院 消化器化学療法科)

**Perspectives for clinical trials in upper GI cancer**  
Sylvie Lorenzen (Department of Hematology and Oncology)

## Meet the Experts会場② (国立京都国際会館 2階 Room J)

8:20-9:20 Meet the Experts 10

### ME10 Liquid biopsy in the era of precision oncology

E

Chair : Yasuhiro Koh (Center for Biomedical Sciences, Wakayama Medical University)  
司会 : 洪 泰浩 (和歌山県立医科大学 バイオメディカルサイエンスセンター)

#### Liquid biopsy in the era of precision oncology

Ryan B. Corcoran (Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA USA)

9:35-10:35 Meet the Experts 11

### ME11 The role of exercise in cancer survivorship: Past, present and future

E

Chairs : Eisuke Ochi (Faculty of Bioscience and Applied Chemistry/Graduate School of Sports & Health Studies, Hosei University)  
司会 : 越智 英輔 (法政大学 生命科学部/スポーツ健康学研究科)

#### The role of exercise in cancer survivorship: Past, present and future

Kristin L. Campbell (Department of Physical Therapy, University of British Columbia)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

ポスター会場 (国立京都国際会館 1階 ニューホール)

11:30-12:15 Poster Session 32 / ポスターセッション 32

**P32** Hematologic Malignancies 2  
血液2

- P32-1 **TP-3654, an oral PIM kinase inhibitor, in intermediate-2 or high-risk primary or secondary myelofibrosis: Phase 1 Study**  
Sujan Kabir (Sumitomo Dainippon Pharma Oncology, Inc.)
- P32-2 **G-CVP therapy using obinutuzumab for follicular lymphoma**  
Toshiki Yamada (Department of Hematology, Gifu Prefectural General Medical Center)  
**濾胞性リンパ腫に対するG-CVP療法の使用経験**  
山田 俊樹 (岐阜県総合医療センター 血液内科)
- P32-3 **A retrospective study of the risk classification of AML with or without the genetic analysis in a single institution**  
Yuhei Shibata (Department of Hematology, Gifu Municipal Hospital)  
**単施設における遺伝子情報の有無による急性骨髄性白血病のリスク分類の後方視的検討**  
柴田 悠平 (岐阜市民病院)
- P32-4 **Retrospective study of mantle cell lymphoma; a single center practice**  
Hiroyuki Takahashi (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)  
**当院におけるマンツル細胞リンパ腫治療の後方視的検討**  
高橋 寛行 (神奈川県立がんセンター 血液・腫瘍内科)
- P32-5 **The usefulness of bone marrow examination in the diagnosis of patients with splenomegaly**  
Chisato Mizutani (Department of Hematology, Japanese Red Cross Hospital of Osaka)  
水谷 知里 (大阪赤十字病院)
- P32-6 **Risk factors associated with mortality following ICU admission in patients with hematologic malignancies**  
Haruhi Furukawa (Department of Hematology, National Cancer Center Hospital / The Jikei University Graduate School of Medicine)  
古川 晴斐 (国立がん研究センター中央病院 血液腫瘍科 / 東京慈恵会医科大学大学院医学研究科)
- P32-7 **Efficacy of Carfilzomib-containing rescue chemotherapy followed by HDT/2nd ASCT in relapsed multiple myeloma patients**  
Shinsuke Mizutani (Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine)  
水谷 信介 (京都府立医科大学 内科学教室 血液内科学部門)
- P32-8 **Outcome of patients with B-cell non-Hodgkin lymphoma who received second-line salvage regimens: A retrospective study**  
Yu Yagi (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center)  
**再発・難治性非ホジキンB細胞性リンパ腫におけるセカンドサルベージ療法の検討**  
八木 悠 (都立駒込病院)

P32-9 **Efficacy and safety of R-GCD regimen in heavily pretreated elderly patients with R/R aggressive B-cell lymphoma**

Toshiya Hino (Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo)

日野 俊哉 (東京大学大学院医学系研究科 血液・腫瘍内科)

P32-10 **Rituximab induced acute thrombocytopenia in primary bone marrow low grade B-cell lymphoma : case report**

Soichiro Fujii (Department of Hematology, Japanese Red Cross Okayama Hospital)

**Rituximab induced acute thrombocytopenia を合併した骨髄原発低悪性度B細胞リンパ腫**  
藤井 総一郎 (岡山赤十字病院 血液内科)

P32-11 **Synchronous multiple primary tumors in patients with malignant lymphoma: A retrospective study**

Mano Mino (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

美野 真乃 (がん・感染症センター東京都立駒込病院 腫瘍内科)

P32-12 **MYC expression determined by Immunohistochemistry is predictive of poor prognosis of diffuse large B-cell lymphoma**

Sayaka Suzuki (Department of Hematology, Tottori University Hospital / Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University)

**びまん性大細胞型B細胞リンパ腫におけるMYC発現の免疫組織化学的検討と臨床的予後の解析**  
鈴木 さやか (鳥取大学医学部附属病院血液内科 / 鳥取大学医学部病態解析医学講座臨床検査医学分野)

11:30-12:15 Poster Session 33 / ポスターセッション 33

P33

Breast Cancer (Basic science, Biomarker)  
乳腺(基礎研究・バイオマーカー)

P33-1 **L-lysine increase the anticancer effect of Doxorubicin in breast cancer: Relevance of the oxidative stress and autophagy**

Kamran Mansouri (Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical sciences, Kermanshah, Iran)

P33-2 **PARP inhibitor has synergic effect with mTOR inhibitor or E2 for treatment-resistant model cells of ER(+)breast cancer**

Minori Tsukahara (Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University)

**ER陽性進行再発乳癌の治療耐性獲得模倣細胞株において、PARP阻害薬はmTOR阻害薬やエストロゲンとの併用効果を発揮する**  
塚原 美理 (東北大学大学院 医学系研究科 分子機能解析学分野)

P33-3 **Prognostic impact of co-expression of LLGL2 and SLC7A5 in ER $\alpha$ -positive breast cancer patients**

Tomoka Hisada (Department of Breast Surgery, Nagoya City University Graduate School of Medical Science)

**ER陽性乳癌においてLLGL2とSLC7A5の共発現は独立した予後不良因子である**  
久田 知可 (名古屋市立大学大学院 医学研究科 乳腺外科学分野)

Day 1 (Thu)  
Day 2 (Fri)

Day 3 (Sat)  
Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the  
Experts

Poster

Day 1 (Thu)	11:30-12:15	Poster Session 34 / ポスターセッション 34
Day 2 (Fri)	<b>P34</b>	Breast Cancer (Biomarker TR) 乳腺 (バイオマーカー・トランスレーショナルリサーチ)
Day 3 (Sat)	P34-1	<b>Detection of association of LSP1 genetic polymorphisms with breast cancer risk in the Bangladeshi population</b> Mohammad Safiqul Islam (Department of Pharmacy, Noakhali Science and Technology University)
Room 1	P34-2	演題取下
Room 2	P34-3	<b>Clinical and immunological analysis of neoantigen in breast cancer</b> Takafumi Morisaki (Department of Surgery and Oncology, Kyushu University / Fukuoka General Cancer Clinic) <b>乳癌におけるネオアンチゲンの臨床のおよび免疫学的解析</b> 森崎 隆史 (九州大学 臨床腫瘍外科 / 福岡がん総合クリニック)
Room 3		
Room 4	11:30-12:15	Poster Session 35 / ポスターセッション 35
Room 5	<b>P35</b>	Genitourinary Cancer (Prostate cancer) 泌尿器 (前立腺がん)
Room 6	P35-1	<b>Erectile Dysfunction in Patients with Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy</b> Alfredo V. Chua (Division of Medical Oncology, Department of Medicine, University of the Philippines-Philippine General Hospital)
Room 7	P35-2	<b>Chemoresistant role of AMPK induced docetaxel-resistance in human prostate cancer</b> Tzyh-chyuan Hour (Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan / Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan)
Room 8		
Room 9	P35-3	<b>Cabazitaxel in castration-resistant prostate carcinoma: clinical outcome depending on the dosage</b> Momoko Kobayashi (Department of Urology, Kitasato University) <b>去勢抵抗性前立腺癌に対するCabazitaxel療法：投与量別のクリニカルアウトカム</b> 小林 桃子 (北里大学医学部泌尿器科)
Room 10		
Room 11	P35-4	<b>Corticosteroid Switch in Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone: A Systematic Review</b> Michele Indrawan (Faculty of Medicine, Pelita Harapan University)
Room 12	P35-5	<b>Significance of early PSA response in prognostic factors for de novo mHSPC</b> Kenichi Tabata (Department of Urology, Kitasato University School of Medicine) 田畑 健一 (北里大学)
Room 13	P35-6	<b>Detection rate of BRCA2 mutation in prostate cancer patients: Initial experience at our institute</b> Ryoma Kurahashi (Department of Urology, Faculty of Life Sciences, Kumamoto University) 倉橋 竜磨 (熊本大学大学院生命科学研究部泌尿器科学講座)
Meet the Experts		
Poster		



P35-7 **Analysis of BRCA1/2 mutations for metastatic castration resistant prostate cancer in clinical practice**

Kazutoshi Fujita (Department of Urology, Kindai University Faculty of Medicine)  
藤田 和利 (近畿大学医学部)

P35-8 **BRCA mutation test for castration-resistant prostate cancer in Iwate prefecture, Japan**

Shigekatsu Maekawa (Department of Urology, Iwate Medical University)

**岩手県における去勢抵抗性前立腺癌に対するBRCA遺伝子変異検査について**  
前川 滋克 (岩手医科大学 泌尿器科)

P35-9 **Association between the timing or the number of Radium-223 and survival of CRPC patients with bone metastases**

Hitomi Yasukawa (Department of Urology, University of Toyama)

安川 瞳 (富山大学学術研究部医学系 腎泌尿器科学講座)

P35-10 **Our experience of management of rash caused by apalutamide**

Natsuo Kimura (Department of Urology, Asahi General Hospital)

**当院におけるapalutamideの副作用の皮疹のマネージメント**  
木村 夏雄 (国保旭中央病院 泌尿器科)

11:30-12:15 Poster Session 36 / ポスターセッション 36

P36

Rare Cancer/Cancer of Unknown Primary (Miscellaneous)  
希少がん・原発不明がん(その他)

P36-1 **Reappraisal of surgical decision-making in patients with splenic sclerosing angiomatoid nodular transformation**

Hao Tseng (Department of Surgery, National Taiwan University Hospital)

P36-2 **Mortality or survival risk of pregnant women with Malignant Melanoma: A systematic Review**

Ester Elita Sumbayak (Faculty of Medicine, Pelita Harapan University)

P36-3 **Malignant primary cardiac tumors and the cautionary cardiotoxicities**

Kanami Furukawa (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital)

古川 佳那美 (九州大学病院 血液・腫瘍・心血管内科)

P36-4 **Metastatic Lesions of the Clivus: A Systematic Review**

Felix Jozsa (National Hospital for Neurology and Neurosurgery, Queen Square, London)

P36-5 **Dissecting Intratumoral Heterogeneity of Sarcomatoid RCC Arising from Autosomal Dominant Polycystic Kidney Disease**

Elizabeth Lee (Laboratory of Cancer Epigenome, National Cancer Centre Singapore)

P36-6 **Longitudinal observational study of lenvatinib-associated AEs in patients with advanced differentiated thyroid cancer**

Yuka Aida (Department of Medical Oncology, University of Tsukuba)

**切除不能放射性ヨウ素治療抵抗性分化型甲状腺癌患者におけるレンバチニブ関連有害事象の経時的観察研究**

會田 有香 (筑波大学附属病院 腫瘍内科)

Day 1 (Thu)	P36-7	<b>A study on the order of immune checkpoint inhibitors and radiotherapy for unresectable malignant melanoma</b> Akinori Kobayashi (Department of Medical Oncology, Kameda Medical Center) 小林 哲徳 (亀田総合病院)
Day 2 (Fri)	P36-8	<b>Single centre experience of various operable primary axillary masses and their management</b> Nikhil Garg (Department of Surgical Oncology, AIIMS Bathinda, India)
Day 3 (Sat)	P36-9	<b>Dosimetric comparison of coplanar, non-coplanar and multi-planar VMAT for radiotherapy patients with primary brain tumor</b> Eva Y W Cheung (School of Medical and Health Sciences, Tung Wah College, Hong Kong)
Room 1	P36-10	<b>BuTT High-dose chemotherapy supported by autologous stem cell transplant in relapsed or refractory primary CNS lymphoma</b> Motoo Nagane (Department of Neurosurgery, Kyorin University Faculty of Medicine) <b>再発・難治性中枢神経系原発悪性リンパ腫に対する自家幹細胞移植支援BuTT大量化学療法 の初期経験</b> 永根 基雄 (杏林大学医学部 脳神経外科)
Room 2	P36-11	<b>Neuroendocrine carcinoma of unknown primary with syndrome of inappropriate antidiuretic hormone secretion: a case report</b> Hiroshi Matsumoto (Department of Gastroenterology, Shiga University of Medical Science) <b>SIADHを伴った原発不明神経内分泌癌の一例</b> 松本 寛史 (滋賀医科大学医学部附属病院 消化器内科)
Room 3	P36-12	<b>A Case of Progressing Mesenteric Desmoid Fibromatosis: A Diagnostic and Therapeutic Challenge</b> Paula Isabel G. Franco (Section of Medical Oncology, St. Luke's Medical Center)
Room 4	P36-13	<b>The efficacy of Nivolumab in malignant melanoma patients: a systematic review</b> Alicia Valerine (Faculty of Medicine, Pelita Harapan University)
Room 5	P36-14	<b>Ibrutinib in refractory or relapsing Primary Central Nervous System Lymphoma: a systematic review</b> Gaurav Nepal (Department of Internal Medicine, Tribhuvan University Teaching Hospital)
Room 6	P36-15	<b>Long term outcome of surgical management for vertebral hemangioma presenting with myelopathy</b> Pankaj Kumar Singh (Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi)
Room 7	11:30-12:15 Poster Session 37 / ポスターセッション 37	
Room 8	P37 Translational Research/Clinical Pharmacology (Case Report) TR・臨床薬理(ケースレポート)	
Room 9	P37-1	<b>Liquid biopsy for the detection of the resistant mutation to ROS1 and RET inhibitors: A case series study</b> Yoshitaka Seki (Division of Respiriology, Department of Internal Medicine, The Jikei University Katsushika Medical Center) 関 好孝 (東京慈恵会医科大学 葛飾医療センター 呼吸器内科)
Room 10		
Room 11		
Room 12		
Room 13		
Meet the Experts		
Poster		

P37-2 **NaHCO<sub>3</sub> promoter of bacterial lysis in CVC and activation of cytokines release of fever in pediatric oncological patients**  
Guillermo O. Rocabado (Department of Medical Oncology Children Hospital Bolivia)

11:30-12:15 Poster Session 38 / ポスターセッション 38

**P38** Translational Research/Clinical Pharmacology (Precision Medicine 2)  
TR・臨床薬理 (ゲノム医療2)

P38-1 **The clinical result of cancer multi gene panel testing in Anjo Kosei Hospital**  
Yuichiro Inagaki (Department of Hematology and Oncology, Anjo Kosei Hospital)  
**当院におけるがん遺伝子パネル検査症例の臨床的有効性の検討**  
稲垣 裕一郎 (安城更生病院 血液・腫瘍内科)

P38-2 **Comprehensive genomic profiling using a liquid biopsy in patients with advanced solid tumors**  
Reiko Kimura-Tsuchiya (Department of Clinical Oncology, Kyoto University Hospital)  
木村 礼子 (京都大学医学部附属病院腫瘍内科)

P38-3 **Clinical outcomes of next-generation sequencing test for breast cancer at the National Cancer Center Hospital**  
Rumi Nishimura (Department of Medical Oncology, National Cancer Center Hospital)  
西村 瑠美 (国立がん研究センター中央病院 腫瘍内科)

P38-4 **A study of the Oncomine Dx Target Test in bronchoscopic specimens of non-small cell lung cancer cases**  
Atsuhiko Yatani (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine)  
矢谷 敦彦 (神戸大学大学院医学研究科 内科学講座・呼吸器内科学分野)

P38-5 **EGFR-mutated lung cancer cells accelerate the release of cfDNA activating innate immune pathways upon EGFR-TKI treatment**  
Takuro Noguchi (Department of Medical Oncology, Hokkaido University)  
野口 卓郎 (北海道大学 腫瘍内科)

P38-6 **Evaluation of annotations for cancer gene panel testing using a genome-guided system**  
Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine / Center for Genomic Medicine, St. Marianna University School of Medicine Hospital)  
**ゲノムガイドシステムを用いたがん遺伝子パネル検査のアノテーションの評価**  
砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座 / 聖マリアンナ医科大学病院 ゲノム医療推進センター)

P38-7 **Germline Findings detected by cancer genomic profiling and examination of genetic counseling for patients and families**  
Miwa Arita (Department of Clinical Genetics, University of Tsukuba Hospital)  
**がん遺伝子パネル検査で検出されたGermline Findingsと患者・家族への遺伝カウンセリングの検討**  
有田 美和 (筑波大学附属病院 遺伝診療部)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

P38-8 **Current status and issue of the cancer genomic profiling test in our hospital, including genetic counseling**  
 Akihiro Shinji (Department of Medical Oncology, Suwa Red Cross Hospital)  
**当院におけるがん遺伝子パネル検査の現状と課題～二次的所見に対する遺伝カウンセリングも含めて**  
 進士 明宏 (諏訪赤十字病院 腫瘍内科)

P38-9 **Evaluation and comparison of dengue NS1, chikungunya and HCV: fluorescence assay with rapid immunochromatographic test**  
 Md Shariful Islam (University of kentucky, USA / Scientific Officer, Japan Medical and Research Center, Dhaka, Bangladesh / Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University)

11:30-12:15 Poster Session 39 / ポスターセッション 39

**P39** Cross-sectional Program (ICI)  
 臓器横断プログラム (免疫チェックポイント阻害薬の副作用)

P39-1 **A clinical study of 11 cases of immune checkpoint inhibitor-induced adrenal insufficiency**  
 Shogo Watanabe (Department of Medical Oncology, Toranomon Hospital)  
**免疫チェックポイント阻害剤が誘発した副腎不全11症例の臨床的検討**  
 渡辺 祥伍 (虎の門病院臨床腫瘍科)

P39-2 **How to deal with the side effects of the eye findings of immune check inhibitors**  
 Hideko Akagi (Department of Oncology, Keiyu Hospital)  
**免疫チェック阻害剤の眼所見の副作用はどの位起こるのだろうか？その対処法は？**  
 赤木 秀子 (けいゆう病院 腫瘍内科)

P39-3 **Our Department's Status of Thyroid Immune-Related Adverse Events and Its Management for PD-1 and PD-L1 Inhibitors**  
 Masako Inoue (Department of Medical Oncology, Matsudo City General Hospital)  
**当院化学療法内科において抗PD-1抗体、抗PD-L1抗体使用における甲状腺に関する免疫関連有害事象の発症状況とその対策**  
 井上 真佐子 (松戸市立総合医療センター 化学療法内科)

P39-4 **Efficacy of Pembrolizumab in the Treatment of MSI-High Tumors Other Than Colorectal Cancer at Our Institution**  
 Shinichi Nishina (Department of Medical Oncology, Kurashiki Central Hospital)  
**当院における大腸癌以外のMSI-Highのがんに対するPembrolizumabの治療効果**  
 仁科 慎一 (倉敷中央病院 腫瘍内科)

P39-5 **免疫チェックポイント阻害薬投与患者におけるCD4/8比と免疫関連有害事象発現状況の関連についての後ろ向き調査**  
 Hiroko Kado (Department of Pharmacy, NTT Medical Center Tokyo)  
 加戸 寛子 (NTT東日本関東病院 薬剤部)

P39-6 **Nutritional factors related to immune-related adverse events**  
 Kaori Kawana (Department of Nutrition, Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
**免疫関連有害事象(irAEs)に関する栄養学的因子について**  
 川名 加織 (がん研究会有明病院 栄養管理部)

P40	Patient Advocacy/Survivorship 患者支援・サバイバーシップ
P40-1	<p><b>The retrospective study investigating the usefulness of the critical path for supportive care post chemotherapy</b> Tsutomu Takahashi (Department of hematology, Shimane University Hospital)</p> <p>化学療法後の病診連携クリティカルパス(G-CSF予防投与クリティカルパス)の有用性に関する後方視的検討 高橋 勉 (島根大学医学部附属病院 血液内科)</p>
P40-2	<p><b>A retrospective analysis of consulters manifesting "crying" in consult at the cancer consultation room</b> Mayumi Haruta (Division of Clinical Oncology, Nagoya City University)</p> <p>当院のがん包括ケア支援室における相談者の「泣き」事例の後方視的解析と考察 春田 真弓 (名古屋市立大学病院 臨床腫瘍部)</p>
P40-3	<p><b>Looking back on cancer consultations provided by certified cancer chemotherapy nursing nurses</b> Ken Kawaminami (Saiseikai Senri Hospital)</p> <p>がん化学療法看護認定看護師が行ったがん相談を振り返る 川南 健 (大阪府済生会千里病院)</p>
P40-4	<p><b>看護相談外来における高齢がん患者への支援の形</b> Kozue Yoshida (Takarazuka City Hospital)</p> <p>吉田 こずえ (宝塚市立病院)</p>
P40-5	<p><b>入院中のAYA世代がん患者に対する苦痛スクリーニング ～がん看護外来への連携の現状と課題～</b> Emi Nagaishi (Nagasaki University Hospital)</p> <p>永石 恵美 (長崎大学病院)</p>
P40-6	<p><b>Current State and Satisfaction Surveys for User of Cancer Consultation Support Center at Fukuoka University Hospital</b> Toshihiro Tanaka (Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Fukuoka University)</p> <p>福岡大学病院がん相談支援センターの現状と課題に関する調査 田中 俊裕 (福岡大学病院 腫瘍血液感染症内科)</p>
P40-7	<p><b>コロナ禍におけるがん患者の就労の現状と支援</b> Yuka Kawasaki (General Incorporated Association Gan Life Adviser)</p> <p>川崎 由華 (一般社団法人がんライフアドバイザー協会)</p>
P40-8	<p><b>三次治療以降における進行大腸がん患者と医療者との気持ちの隔たり －患者の闘病記及び診療録による調査から－</b> Mayumi Nakai (National Hospital Organization Nagoya Medical Center Nursing Department)</p> <p>中井 真由美 (名古屋医療センター 看護部)</p>
P40-9	<p><b>Continued report on the Cancer Salon at Jichi Medical University Hospital - Restart under the COVID-19 pandemic</b> Rie Yamamoto (Mental Health Care Center, Jichi Medical University Hospital)</p> <p>自治医科大学附属病院がんサロンの活動続報 - COVID-19流行下の再開 - 山本 理栄 (自治医科大学附属病院 こころのケアセンター)</p>

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Poster Experts

P40-10

## AMH (anti-Mullerian hormone) as ovarian function before and after chemotherapy in young breast cancer patients

Toshiko Miyaki (Breast Surgery, Chiba Cancer Center)

若年乳癌患者における化学療法前後の卵巣予備能AMH (抗ミュラー管ホルモン) に関する検討  
味八木 寿子 (千葉県がんセンター 乳腺外科)

Day 1 (Thu)  
Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

ポスター会場 (国立京都国際会館 1階 イベントホール)

11:30-12:15 Poster Session 41 / ポスターセッション 41

P41 Gastrointestinal Cancer (Case Report 2)  
消化器(ケースレポート2)

- P41-1 **ペムプロリズマブ使用中に下垂体機能低下症と間質性肺炎を発症したが診療科横断的に治療できた高頻度マイクロサテライト不安定性大腸癌の1例**  
Kunitoshi Shigeyasu (Department of Enterological Surgery, Okayama University)  
重安 邦俊 (岡山大学 消化器外科)
- P41-2 **Long-term survival of HER2+ gastric cancer with multiple liver metastasis and severe liver failure by using Nivolumab**  
Kanako Yokomizo (Department of Medical Oncology, Shimane University)  
**多発肝転移を有し、重度の肝不全を呈したHER2陽性胃癌に対してニボルマブ投与で改善が得られ、長期生存が可能となった一例**  
横溝 加奈子 (鳥根大学医学部付属病院 腫瘍内科)
- P41-3 **Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL) in the jejunum and gall bladder:A case report**  
Mari Nakagawa (Department of Gastroenterology, Shinmatsudo Central General Hospital)  
**空腸と胆嚢に発症したMonomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL)の1例**  
中川 真理 (新松戸中央総合病院 消化器病センター)
- P41-4 **血液透析患者の上行結腸がんに対しmFOLFOX6+Bevacizumab療法を施行した1例**  
Ayumi Ozeki (Department of Pharmacy, Shonantobu General Hospital)  
尾関 あゆみ (湘南東部総合病院 薬剤科)
- P41-5 **A case of advanced gastric cancer treated successfully with Nivolumab**  
Junji Kawada (Department of Surgery, Yao Municipal Hospital)  
川田 純司 (八尾市立病院)
- P41-6 **A case of gastric adenocarcinoma with enteroblastic differentiation successfully treated with SOX therapy**  
Kazuhiro Kishi (Department of gastroenterology, Tokushima Red Cross Hospital)  
**SOX療法が著効した胃胎児消化管上皮類似癌の1例**  
岸 和弘 (徳島赤十字病院 消化器内科)
- P41-7 **Two cases of BRAF mutant mCRC with intestinal stenosis responded to encorafenib + binimetinib + cetuximab: A case report**  
Ikuhiro Kita (Department of Clinical Oncology, Kagawa University Faculty of Medicine)  
**エンコラフェニブ+ビニメチニブ+セツキシマブ (BEACON-3) 療法が奏効した腫瘍性腸閉塞を有するBRAF変異陽性大腸がんの2例**  
喜田 行洋 (香川大学医学部 臨床腫瘍学)
- P41-8 **Interaction of warfarin and lenvatinib in a patient with hepatocellular carcinoma**  
Yoshiharu Suzuki (Department of Pharmacy, Ibaraki Prefectural Central Hospital)  
**ワルファリンとレンパチニブとの薬物間相互作用を認めた肝細胞癌の一例**  
鈴木 嘉治 (茨城県立中央病院・茨城県地域がんセンター 薬剤局薬剤科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)	P41-9	<b>A case of DPD deficiency in a patient who suffered from severe mFOLFOX6-related adverse events</b> Taichi Abe (Pharmaceutical Department, Yokohama City Minato Red Cross Hospital) <b>mFOLFOX6投与により重篤な有害事象をきたしたDPD欠損症の1例</b> 阿部 多一 (横浜市立みなと赤十字病院 薬剤部)
Day 2 (Fri)	P41-10	<b>Successful treatment with nivolumab in a patient with advanced esophageal cancer and concomitant Graves' disease</b> Yosuke Miura (Division of Allergy and Respiratory Medicine, Gunma University Hospital) <b>バセドウ病合併進行食道癌に対し、安全にニボルマブを投与できた1例</b> 三浦 陽介 (群馬大学医学部附属病院 呼吸器・アレルギー内科)
Day 3 (Sat)	P41-11	<b>mFOLFOX6療法中に器質性肺炎を発症し死亡したIgG4関連ミクリッツ病合併切除不能進行胃癌の一例</b> Shoko Nakajima (Saiseikai Central Hospital) 中島 菖子 (東京都済生会中央病院)
Room 1	P41-12	<b>Rapid progression of metastatic colorectal cancers following cessation of BRAF, MEK and EGFR inhibition</b> Haruhiko Sano (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University) <b>BRAF、MEK、EGFR阻害薬中止後に急速増大をきたした進行大腸癌</b> 佐野 晴彦 (佐賀大学医学部附属病院 血液呼吸器腫瘍内科)
Room 2	11:30-12:15 Poster Session 42 / ポスターセッション 42	
Room 3	<b>P42</b> Gastrointestinal Cancer (Esophageal Cancer 2) 消化器(食道2)	
Room 4	P42-1	<b>Correlation of PD-L1 expression and clinical efficacy for advanced ESCC treated with nivolumab monotherapy</b> Hayato Mikuni (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital / Department of Gastroenterology and Hepatology, Jikei University Hospital) 三國 隼人 (国立がんセンター中央病院 頭頸部・食道内科 / 東京慈恵会医科大学附属病院 消化器・肝臓内科)
Room 5	P42-2	<b>Real World Data on Immune Checkpoint Inhibitors as Later Line Treatment for Esophageal Cancer</b> Shunsuke Ueyama (Division of Gastroenterology, Tsuchiura Kyodo General Hospital) 上山 俊介 (土浦協同病院 消化器内科)
Room 6	P42-3	<b>Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer</b> Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital) 前田 修 (名古屋大学医学部附属病院 化学療法部)
Room 7	P42-4	<b>Clinical experiences of combination therapy with cisplatin for the older-aged esophageal cancer patients</b> Masahiro Hatori (Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research) 羽鳥 正浩 (公益財団法人がん研究会 有明病院 薬剤部)
Room 8	Meet the Experts	
Room 9	Poster	



- P42-5 **Optimal primary prophylaxis for febrile neutropenia during docetaxel, cisplatin, and 5-FU therapy for esophageal cancer**  
Ryosuke Kumanishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
熊西 亮介 (愛知県がんセンター薬物療法部)
- P42-6 **Can chemoradiation with triplet regimen alternate surgery for esophageal cancer ??: a propensity-score matching analysis**  
Hiroyuki Ohnuma (Department of Medical Oncology, Sapporo Medical University School of Medicine)  
大沼 啓之 (札幌医科大学 腫瘍内科)
- P42-7 **FOLFOX-based chemoradiotherapy for locally advanced/metastatic esophageal squamous cell carcinoma with severe dysphagia**  
Kazuhiro Shiraiishi (Department of Medical Oncology, National Hospital Organization Nagoya Medical Center)  
白石 和寛 (名古屋医療センター 腫瘍内科)
- P42-8 **An Initial Experience of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) from A Tertiary Centre in Western India**  
Jeewan Ram Vishnoi (Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India)
- P42-9 **Radiomic Signature predicated the Efficacy of Neo-adjuvant Immunotherapy in Esophageal squamous cell carcinoma Patients**  
Jianhua Liu (Guangdong Provincial People's Hospital)
- 11:30-12:15 Poster Session 43 / ポスターセッション 43
- P43** Hepatobiliary/Pancreatic Cancer (Pancreatic Cancer 1)  
肝胆腫(臓臓1)
- P43-1 **膵癌におけるFOLFIRINOXの予測因子としてのBRCA病的変異の有用性についての検討**  
Shigeru Horiguchi (Department of Gastroenterology, Okayama University)  
堀口 繁 (岡山大学病院 消化器内科)
- P43-2 **Successful treatment of carcinomatose peritoni from pancreatic cancer using nal-IRI + FF therapy as third-line treatment**  
Takahisa Fujikawa (Department of Surgery, Kokura Memorial Hospital)  
膵癌腹膜播種に対し三次治療としてナノリボソーム型イリノテカン+フルオロウラシル/フォリン酸(nal-IRI+FF)療法が著効した1例  
藤川 貴久 (小倉記念病院)
- P43-3 **Comparison of FOLFIRINOX and Gemcitabine plus Nab-paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review**  
Greg Faldo (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P43-4 **Multicenter retrospective study of first-line to second-line chemotherapy in unresectable pancreatic cancer**  
Tatsuki Ikoma (Department of Medical Oncology, Osaka Red Cross Hospital / Department of Medical Oncology, Kobe City Medical Center General Hospital)  
生駒 龍興 (大阪赤十字病院 腫瘍内科 / 神戸市立医療センター中央市民病院 腫瘍内科)

Day 1 (Thu)	P43-5	<b>Nal-IRI/5-FU/LV, modified FOLFIRINOX, and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer</b> Shun Tezuka (Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center) 手塚 瞬 (神奈川県立がんセンター)
Day 2 (Fri)	P43-6	<b>Efficacy of Stereotactic Body Radiation Therapy with Gemcitabine in Advanced Pancreatic Cancer: A Systematic Review</b> Audrey Hadisurya (Faculty of Medicine, Pelita Harapan University)
Day 3 (Sat)	P43-7	<b>Baseline Differences in Hypertensive and Non-hypertensive Patients with Advanced Pancreatic Cancer</b> Kiyotsugu Iede (Department of Clinical Oncology, Higashiosaka City Medical Center) 家出 清継 (市立東大阪医療センター)
Room 1	P43-8	<b>Efficacy and safety of modified FOLFIRINOX after progression on 1<sup>st</sup>-line treatment in unresectable pancreatic cancer</b> Rina Ueki (Department of Gastroenterology and Hepatology, The Jikei University School of Medicine) 植木 里奈 (東京慈恵会医科大学 消化器・肝臓内科)
Room 2	P43-9	<b>Retrospective analysis of gemcitabine plus nab-paclitaxel for pancreatic cancer with malignant ascites</b> Kanae Inoue (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East) 井上 佳苗 (国立がん研究センター東病院)
Room 3	P43-10	<b>The analysis of forty-one unresectable or metastatic pancreatic cancer patients received with nanoliposomal irinotecan</b> Shogen Boku (Cancer Treatment Center, Kansai Medical University) 朴 将源 (関西医科大学附属病院 がんセンター)
Room 4	P43-11	<b>Clinical outcomes of nal-IRI plus 5-FU/LV with unresectable pancreatic cancer refractory to GEM plus nab-PTX in Japan</b> Masashi Ishikawa (Division of Gastroenterology and Hepatology, The Jikei University School of Medicine) 石川 将史 (東京慈恵会医科大学 消化器・肝臓内科)
Room 5	11:30-12:15 Poster Session 44 / ポスターセッション 44	
Room 6	<b>P44</b>	Lung Cancer/Thoracic Cancer (Genome biomarker) 呼吸器 (遺伝子 バイオマーカー)
Room 7	P44-1	<b>Discrepancy in MET exon 14 skipping mutation measurement between ArcherMET and OncoPrint Dx Target Test system</b> Kanao Shinada (Department of Thoracic Oncology, Kanagawa Cancer Center) <b>MET exon 14 skipping変異におけるArcherMETとOncoPrint Dx Target Test Systemとの結果不一致についての検討</b> 品田 佳那子 (神奈川県立がんセンター 呼吸器内科)
Room 8	P44-2	<b>Comparison of modalities for evaluation of MET exon 14 skipping mutation in non-small-cell lung cancer</b> Yuki Shinno (Department of Thoracic Oncology, National Cancer Center Hospital) 新野 祐樹 (国立がん研究センター中央病院 呼吸器内科)
Room 9		
Room 10		
Room 11		
Room 12		
Room 13		
Meet the Experts		
Poster		

- P44-3 **Reflections on the tests and treatments performed for incurable advanced non-small cell lung cancer at our hospital**  
Kiyohide Komuta (Department of Respiratory Medicine, Osaka General Medical Center)  
小牟田 清英 (大阪急性期・総合医療センター 呼吸器内科)
- P44-4 **Analysis of Oncomine Dx Target Test at our hospital and its usefulness in clinical practice**  
Shinji Chiba (Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University)  
千葉 真士 (岩手医科大学 内科学講座 呼吸器内科分野)
- P44-5 **Daily use of NGS for lung cancer in our hospital**  
Takeshi Kaihara (Clinical Oncology, Toyama University Hospital)  
**当院での日常診療における肺癌患者次世代シーケンス検査の検討**  
貝原 毅 (富山大学附属病院 臨床腫瘍部)

11:30-12:15 Poster Session 45 / ポスターセッション 45

**P45** Lung Cancer/Thoracic Cancer(Case Report)  
呼吸器(ケースレポート)

- P45-1 **A case of small cell lung carcinoma after single lung transplantation treated with multi-modality therapy**  
Takashi Inoue (Cancer Medical Treatment Center, Dokkyo Medical University / Department of General Thoracic Surgery, Dokkyo Medical University)  
**肺移植後残存肺に発生した原発性肺癌に対し集学的治療を施行した1例**  
井上 尚 (獨協医科大学病院 総合がん診療センター/獨協医科大学 呼吸器外科)
- P45-2 **Atezolizumab in combination with carboplatin and nab-paclitaxel for combined large-cell neuroendocrine carcinoma**  
Takayuki Takeda (Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital)  
**混合型大細胞神経内分泌癌に対して複合免疫療法が奏効した1例**  
竹田 隆之 (京都第二赤十字病院 呼吸器内科)
- P45-3 **Pembrolizumab-induced oral mucositis in a patient with non-small cell lung carcinoma: A case report**  
Kazuki Tomita (Department of Medical Oncology, Tazuke Kofukai, Medical Research Institute, Kitano Hospital)  
**ペムブロリズマブ治療中に発症し、ステロイド治療で寛解した口腔粘膜炎の一例**  
富田 和輝 (公益財団法人 田附興風会 医学研究所 北野病院 腫瘍内科)
- P45-4 **Hemophagocytic syndrome caused by Immune checkpoint inhibitor therapy in a patient with non-small cell lung cancer**  
Takashi Kurosaki (Department of Medical Oncology, Kindai University Faculty of Medicine)  
**非小細胞肺癌に対する免疫チェックポイント阻害薬投与中に免疫関連有害事象である血球貪食症候群を発症した一例**  
黒崎 隆 (近畿大学医学部内科学腫瘍内科部門)

- P45-5 **Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report**  
Yuki Ikematsu (Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital)  
池松 祐樹 (独立行政法人 国立病院機構 大牟田病院 呼吸器内科)
- P45-6 **Next-generation sequencing by cytological specimens using Lung Cancer Compact Panel**  
Daisuke Minami (Department of Pulmonary Medicine, Hosoya Hospital / Department of Pulmonary Medicine, Himeji St. Mary's Hospital / Internal Medicine 4, Kawasaki Medical School)  
**細胞診検体を用いた肺がんコンパクトパネルによる次世代シーケンシングの使用経験**  
南 大輔 (医療法人ほそや医院 呼吸器内科 / 姫路聖マリア病院 呼吸器内科 / 川崎医科大学 総合内科学4)
- P45-7 **Metachronous onset of double cancer during the long term response with immune checkpoint inhibitor in two NSCLC patients**  
Genju Koh (Department of Oncology, Yao Municipal Hospital / Department of Internal Medicine, Yao Tokushukai Hospital)  
**免疫チェックポイント阻害剤による長期寛解中に異時性重複癌を発症した非小細胞肺癌2症例の検討**  
洪 鉉寿 (八尾市立病院 腫瘍内科 / 八尾徳洲会総合病院 内科)
- P45-8 **The usefulness of liquid biopsy in initial therapy of advanced metastatic non-small cell lung cancer**  
Ryo Sawada (Department of Medical Oncology, Fukuchiyama City Hospital / Department of Respiratory Medicine, Fukuchiyama City Hospital)  
**進行非小細胞肺癌の初回治療時におけるリキッドバイオプシーの有用性**  
澤田 凌 (市立福知山市民病院 腫瘍内科 / 市立福知山市民病院 呼吸器内科)
- P45-9 **Late line ABCP is effective for brain metastases in 3 cases of EGFR mutation positive lung adenocarcinoma**  
Atsushi Muto (Department of Respiratory Medicine, Kurobe City Hospital)  
**Late lineのABCP療法が脳転移に有効であったEGFR遺伝子変異陽性肺腺癌の3例**  
武藤 篤 (黒部市民病院)
- P45-10 **A case of synchronous EGFR mutant lung adenocarcinoma and renal cell carcinoma**  
Noriyuki Ebi (Department of Respiratory Medicine, Fukuoka University Hospital)  
**同時性EGFR肺癌&腎細胞癌の1例**  
海老 規之 (福岡大学病院 呼吸器内科)
- P45-11 **Analysis of 46 genes for non-squamous non-small cell lung cancer resection cases using Oncomine Dx Target Test**  
Riichiro Maruyama (Department of Thoracic Surgery, Social Insurance Omuta Tenryo Hospital)  
**非扁平上皮非小細胞肺癌切除症例を用いたオンコマインDx Target Test マルチ研究用46遺伝子の解析**  
丸山 理一郎 (大牟田天領病院 呼吸器外科)

- P45-12 **Suspected case of Systemic Capillary Leak Syndrome after Nivolumab and Ipilimumab combination therapy for lung cancer**  
Ayako Takigami (Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University)  
**Nivolumab・Ipilimumab併用療法後のSystemic Capillary Leak Syndromeが疑われた肺腺癌の一例**  
瀧上 理子 (自治医科大学内科学講座呼吸器内科学部門)
- P45-13 **Osimertinib-induced interstitial lung disease-addition of tacrolimus to corticosteroids: A case report**  
Toshiyuki Kita (Department of Respiratory Medicine, National Hospital Organization, Kanazawa Medical Center)  
北 俊之 (国立病院機構金沢医療センター呼吸器内科)
- P45-14 **EGFR遺伝子変異陽性の活動性進行肺腺癌と活動性進行直腸癌の同時治療症例の一例**  
Asako Suzuki (Department of Medical Oncology, Sendai Medical Center)  
鈴木 朝子 (国立病院機構 仙台医療センター)
- P45-15 **A Case of Huge Dedifferentiated Solitary Fibrous Tumor**  
Takashi Yoshimatsu (Department of Thoracic Surgery, Fukuoka Wajiro Hospital / Department of Thoracic Surgery, Tokyo Shinagawa Hospital)  
**臍胸と鑑別を要した巨大脱分化型孤立性線維性腫瘍の1切除例**  
吉松 隆 (福岡和白病院 呼吸器外科/東京品川病院 呼吸器外科)
- P45-16 **当院におけるTTF-1陰性進行期肺腺癌に対するカルボプラチン+パクリタキセル+ニボルマブ+イピリムマブ療法の治療経緯**  
Kohei Kushiro (Niigata University Medical and Dental Hospital, Department of Respiratory Medicine and Infectious Diseases)  
久代 航平 (新潟大学医歯学総合病院 呼吸器・感染症内科)
- 11:30-12:15 Poster Session 46 / ポスターセッション 46
- P46** Genitourinary Cancer (Miscellaneous)  
泌尿器(ゲノム・総論・その他)
- P46-1 **Change of patient's perception and expectations over the course of chemotherapy in genitourinary cancer patients**  
Takahito Negishi (Department of Urology, National Hospital Organization Kyushu Cancer Center)  
**転移を有する泌尿器癌患者の化学療法に対する認識とその変化についての検討**  
根岸 孝仁 (九州がんセンター 泌尿器科)
- P46-2 **Initial experience of cancer genomic medicine in urology at Gifu university hospital**  
Koji Inuma (Department of Urology, Gifu University Graduate School of Medicine / Gifu University Hospital, Clinical Genetics Center)  
飯沼 光司 (岐阜大学 泌尿器科/岐阜大学医学部附属病院 ゲノム疾患・遺伝子診療センター)
- P46-3 **Initial report of oncogene panel test in the urological cancer of our hospital**  
Takuya Kondo (Department of Urology, Kanagawa Cancer Center)  
**当院における泌尿器科がんでのがん遺伝子パネル検査の初期報告**  
近藤 拓也 (神奈川県立がんセンター 泌尿器科)

Day 1 (Thu)	P46-4	<b>A case of retroperitoneal giant tumor with genomic diagnosis and use of pembrolizumab</b> Takanobu Motoshima (Department of Urology, Kumamoto University) <b>後腹膜巨大腫瘍でゲノム診断を行いペムブロリズマブを使用した一例</b> 元島 崇信 (熊本大学泌尿器科)
Day 2 (Fri)	P46-5	<b>A case of para-testicular rhabdomyosarcoma</b> Sm Ariful Islam (Dept. of Medical Oncology, National Institute of Cancer Research & Hospital)
Day 3 (Sat)		
Room 1		
Room 2		
Room 3		
Room 4		
Room 5		
Room 6		
Room 7		
Room 8		
Room 9		
Room 10		
Room 11		
Room 12		
Room 13		
Meet the Experts		
Poster		

ポスター会場 (国立京都国際会館 1階 ニューホール)

16:45-17:30 Poster Session 47 / ポスターセッション 47

P47 Gynecologic Cancer 2  
婦人科2

- P47-1 **Improvement of Anti-TIF1- $\gamma$  Antibody positive dermatomyositis after chemotherapy for peritoneal cancer; a case report**  
Shigeki Sato (Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan)  
佐藤 成樹 (金沢大学附属病院 がんセンター)
- P47-2 **A case of MSI-H solid tumor with a long-term response to immune checkpoint inhibitors in combination with local therapy**  
Chihiro Sato (Department of Medical Oncology, Kindai University Hospital)  
**増悪病変に対する局所治療を併用することで免疫チェックポイント阻害薬の長期奏効が得られているMSI-H固形癌の1例**  
佐藤 千尋 (近畿大学病院 腫瘍内科)
- P47-3 **Efficacy and Toxicity of Chemotherapy With or Without Bevacizumab in Cervical Carcinoma: A Systematic Review**  
Cristy Cristhalia Calista Evangelique Hermawan (Faculty of Medicine, Pelita Harapan University)
- P47-4 **Overall Survival of Ovarian Cancer Patients Treated with PLD and Trabectedin: A Systematic Review**  
Greg Faldo (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P47-5 **Discovery of Potential Anti-cancer Agent from Flavonoids through Molecular Docking Simulation Study**  
Mohd Faiz Abd Ghani (Department of Basic Medical Sciences, Universiti Sains Islam Malaysia)
- P47-6 **Efficacy of PARP inhibitor as Promising Treatment for Ovarian Neoplasm: Systematic Review**  
Natasha Karlina Law (Faculty of Medicine, Pelita Harapan University)

16:45-17:30 Poster Session 48 / ポスターセッション 48

P48 Head and Neck Cancer (ICI)  
頭頸部 (ICI)

- P48-1 **Efficacy and safety analysis of nivolumab at a dose of 3mg/kg vs 240mg/body in head and neck squamous cell carcinoma**  
Takuma Kishida (Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center)  
岸田 拓磨 (東京医科大学八王子医療センター 耳鼻咽喉科・頭頸部外科学分野)
- P48-2 **Effect of sarcopenia on the efficacy of immune checkpoint inhibitors in head and neck cancer**  
Norihiro Takemoto (Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine)  
**頭頸部癌においてサルコペニアが免疫チェックポイント阻害薬の効果に与える影響**  
武本 憲彦 (大阪大学大学院医学系研究科耳鼻咽喉科頭頸部外科)

Day 1 (Thu) Day 2 (Fri)	P48-3	<b>Prognostic impact of Metastatic pattern in Squamous Cell Carcinoma of Head and Neck treated with Nivolumab</b> Yuta Hoshi (Department of Head and Neck Surgery, Saitama Cancer Center) <b>頭頸部扁平上皮癌における再発転移部位別で見たニボルマブの治療成績</b> 星 裕太 (埼玉県立がんセンター)
Day 3 (Sat)	16:45-17:30	Poster Session 49 / ポスターセッション 49
Room 1	<b>P49</b>	Head and Neck Cancer (Basic Practice) 頭頸部 (基礎)
Room 2	P49	<b>Epigenetic modifications in betel-nuts related head and neck squamous cell carcinoma in Taiwan</b> Jo-Pai Chen (National Taiwan University Hospital, Yun-lin Branch)
Room 3	16:45-17:30	Poster Session 50 / ポスターセッション 50
Room 4	<b>P50</b>	Head and Neck Cancer (Case Report) 頭頸部 (ケースレポート)
Room 5	P50-1	<b>Juvenile tongue cancer associated with chromosomal fragility (Fanconi anemia)</b> Yoko Obara (Ageo Central General Hospital) <b>染色体の脆弱性 (ファンコニ貧血) に伴う若年性舌癌</b> 小原 陽子 (上尾中央総合病院)
Room 6	P50-2	<b>A fatal case of myocarditis induced by nivolumab treatment for hypopharyngeal cancer</b> Yutaro Usui (Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine) 臼井 佑太郎 (神戸大学医学部附属病院 腫瘍・血液内科)
Room 7	16:45-17:30	Poster Session 51 / ポスターセッション 51
Room 8	<b>P51</b>	Head and Neck Cancer (Miscellaneous) 頭頸部 (その他)
Room 9	P51-1	<b>Prevalence and risk factors of severe weight loss in head and neck cancer patient receiving radiotherapy</b> Wilaiporn Chaidee (Beyond Health Cancer Center, Phyathai Nawamin Hospital, Thailand)
Room 10	P51-2	<b>Central arch mandibular resection and reconstruction: Analysis of outcomes</b> Rahul Yadav (Department of Surgical Oncology, AIIMS Jodhpur)
Room 11	P51-3	<b>Preventive methods of postoperative hypoparathyroidism</b> Kristina Vabalayte (Federal State Budgetary Educational Institution of Higher Education "Saint-Petersburg State University")
Room 12	P51-4	<b>Electroglottography in patients after thyroid surgery</b> Anatoly Romanchishen (Federal State Budgetary Educational Institution of Higher Education "Saint-Petersburg State University")
Room 13		
Meet the Experts	Poster	



- P51-5 **A phase 3 trial of xevinapant + concurrent chemoradiotherapy (CRT) for locally advanced head and neck cancer**  
Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)  
田原 信 (国立がん研究センター東病院 頭頸部内科)
- P51-6 **Response Rate after Brachytherapy in Patient with Oral Squamous Cell Carcinoma**  
Maxim Kotov (NMRC of Oncology named after N.N.Petrov of MoH of Russia)
- P51-7 **Vein preservation strategies to improve the survival rate of the infrahyoid musculocutaneous flap**  
Khoi Anh Nguyen (Department of Maxillofacial Head and Neck Surgery)
- P51-8 **Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer**  
Nobukazu Tanaka (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)  
田中 伸和 (国立がん研究センター東病院 頭頸部内科)
- P51-9 **Weekends-Off Lenvatinib for Radioactive Iodine Refractory Differentiated Thyroid Carcinoma; Case Series**  
Eriko Sato (Department of Otorhinolaryngology, Ehime University)  
佐藤 恵里子 (愛媛大学医学部 耳鼻咽喉科・頭頸部外科)
- P51-10 **Speech and swallowing rehabilitation following tongue reconstruction**  
Dung Phuong Nguyen (Maxillofacial, Head and Neck Surgery, Oncology Hospital Ho Chi Minh City, Vietnam)
- P51-11 **Efficacy and Toxicity of Lenvatinib in unresectable thyroid cancer at Kameda Medical Center**  
Hiroki Kontani (Department of Medical Oncology, Kameda Medical Center)  
紺谷 大貴 (亀田総合病院 腫瘍内科)
- P51-12 **The development of nomogram for predicting thyroid cancer in subject with single thyroid nodule in Bali, Indonesia**  
Citra Aryanti (Division of Surgical Oncology, Department of Surgery, Udayana University, Denpasar, Bali, Indonesia)
- P51-13 **A Systematic Review and Meta-Analysis of Temporal Muscle Thickness in Predicting Outcome in Patients With Glioblastoma**  
Jeremiah H. Wijaya (Faculty of Medicine, Pelita Harapan University)
- P51-14 **Primary Central Nervous System Malignant Melanoma; a case report**  
Shinya Miyamoto (Department of Neurosurgery, Teikyo University Chiba Medical Center)  
**原発性頭蓋内悪性黒色腫の一例**  
宮本 伸哉 (帝京大学ちば総合医療センター)

16:45-17:30 Poster Session 52 / ポスターセッション 52

**P52** Multidisciplinary Team Program (Genome)  
 多職種連携プログラム(ゲノム)

- P52-1 **当院でのがん遺伝子パネル検査の運用と今後の課題**  
 Hanae Shiratori (Tokyo Metropolitan Tama Medical Center)  
 白鳥 花絵 (東京都立多摩総合医療センター)
- P52-2 **当院におけるがんゲノム遺伝子パネル検査の二次的所見疑いの現状報告と今後の対応検討**  
 Eri Yokota (Genomic Medicine Department, Tokyo Metropolitan Tama Medical Center)  
 横田 恵梨 (東京都立多摩総合医療センター ゲノム診療科)
- P52-3 **Collaboration between cancer genomic medicine coordinator and multiple departments in the Genome Medical Department**  
 Masumi Yamazaki (Department of Genomic Medical Affairs, Japan Foundation for Cancer Research Ariake Hospital)  
**ゲノム診療部におけるがんゲノム医療コーディネーターと多部署との連携について**  
 山崎 真澄 (がん研究会有明病院 ゲノム診療部)
- P52-4 **がんゲノム医療を受ける患者の受診動機づけ要因と結果の受容**  
 Ayako Ikemi (Department of Nursing, University of Tsukuba Hospital)  
 池見 亜也子 (筑波大学附属病院 看護部)
- P52-5 **Effort of Cancer Genome Center Hospital in Rural National University**  
 Yoshinaga Okugawa (Department of Genomic Medicine, Mie University Hospital)  
**地方国公立大学病院におけるがんゲノム医療拠点病院としての取り組み**  
 奥川 喜永 (三重大学医学部附属病院 ゲノム医療部)

16:45-17:30 Poster Session 53 / ポスターセッション 53

**P53** Palliative Care/Symptom Management 2  
 緩和ケア・支持療法2

- P53-1 **Novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma**  
 Daisuke Tsutsumi (Department of Pharmacy, Nihon University Itabashi Hospital / School of Pharmacy, Nihon University / Nihon University Itabashi Hospital Tumor Center)  
**B細胞性非ホジキンリンパ腫患者におけるリツキシマブによるインフュージョンリアクションを低減させるための新たなリツキシマブ投与プロトコルの検討**  
 堤 大輔 (日本大学医学部附属板橋病院 薬剤部 / 日本大学薬学部 / 日本大学医学部附属板橋病院腫瘍センター)
- P53-2 **肺がん患者におけるアナモレリンの使用実態調査**  
 Takamichi Arima (Department of Pharmacy, National Cancer Center Hospital)  
 有馬 崇充 (国立がん研究センター中央病院 薬剤部)
- P53-3 **Efficacy and safety of anamorelin for cachexia in patients with gastrointestinal cancer: a retrospective case series**  
 Yudai Shinohara (Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital)  
 篠原 雄大 (JCHO九州病院 血液・腫瘍内科)

- P53-4 **A fact-finding survey of distress and symptom for patients with cancer**  
Kazumasa Yamamoto (Department of Medical Oncology, Toranomon Hospital)  
**がん患者における悩みや副作用に関する実態調査**  
山本 一将 (虎の門病院 臨床腫瘍科)
- P53-5 **Survey of taste disorders in cancer patients**  
Michiyo Kotani (Department of Nursing Osaka International Cancer Institute)  
**がん患者における味覚障害の実態調査**  
小谷 美智代 (大阪国際がんセンター 看護部)
- P53-6 **腹水ろ過濃縮再静注法(CART)後の現状**  
Hiroshi Imada (Tokyo Women's Medical University Medical Center East)  
今田 洋司 (東京女子医科大学東医療センター)
- P53-7 **外来化学療法室での患者からの電話相談の有用性**  
Katsuya Juso (Department of Medical Oncology, Kansai Electric Power Hospital)  
十三 且也 (関西電力病院 腫瘍内科)
- P53-8 **Successfully treated patient with leptomeningeal carcinomatosis-induced balance disorder**  
Taiji Kawasaki (Department of Otolaryngology, Japanese Red Cross Shizuoka Hospital)  
川崎 泰士 (静岡赤十字病院)
- P53-9 **Anamorelin in advanced gastrointestinal cancer patients with cancer cachexia, single center experience**  
Satoru Takeji (Department of Medical Oncology, Hikone Municipal Hospital / Department of Gastroenterology, Hikone Municipal Hospital)  
**当院における消化器がん悪液質に対するアナモレリンの使用経験**  
竹治 智 (彦根市立病院 腫瘍内科/彦根市立病院 消化器内科)
- P53-10 **Ointment of indigo naturalis for chemotherapy-induced oral mucositis: a prospective feasibility study**  
Yuki Saito (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)  
**化学療法誘発性口腔粘膜炎に対する青黛軟膏の前向き安全性確認試験**  
斎藤 優樹 (慶應義塾大学医学部 内科学教室(消化器))
- P53-11 **カバジタキセルの血液毒性に関する安全性の後方視的検討**  
Noriaki Kataoka (Osaka Medical and Pharmaceutical University)  
片岡 憲昭 (大阪医科薬科大学病院)
- P53-12 **Retrospective study of bacteremia in patients receiving cancer chemotherapy**  
Kouya Sawai (Department of Medical Oncology, Tonan Hospital)  
澤井 康弥 (斗南病院 腫瘍内科)
- P53-13 **Examination of the role of the palliative care unit in Covid-19 pandemic**  
Masaoki Sasaki (Department of Medical Oncology, Kyoundo Hospital)  
**コロナ禍における緩和ケア病棟の役割の検討**  
佐々木 政興 (杏雲堂病院 腫瘍内科)

Day 1 (Thu)	P53-14	<b>A fundamental study to develop a comprehensive tool for cancer palliative care using machine learning</b> Kazuki Shimada (Department of Palliative Medicine, Kyoto University Hospital) <b>機械学習によるがん緩和ケアの包括的補助ツール作成についての基盤的検討</b> 嶋田 和貴 (京都大学医学部附属病院 緩和医療科・緩和ケアセンター)
Day 2 (Fri)	P53-15	<b>Use of hypnotic drug was associated with infection in patients aged 80 years or older with diffuse large B-cell lymphoma</b> Anna Ogiso (Department of Clinical Pharmacy, Fujita Health University School of Medicine) 小木曾 杏奈 (藤田医科大学医学部 臨床薬剤科)
Day 3 (Sat)	P53-16	<b>Possible Effect of Blonanserin Transdermal Patch on the Antiemetic Control in Patients with Abdominal or Pelvic Tumors</b> Katsutoshi Ando (Meguro K Home Clinic) <b>腹腔もしくは骨盤内腫瘍に伴う難治性嘔吐に対するブロナンセリンテープ製剤の可能性</b> 安藤 克利 (目黒ケイホームクリニック)
Room 1	P53-17	<b>Efficacy and safety of anamorelin in the treatment of cancer cachexia for unresectable advanced or recurrent cancer</b> Hiroaki Takagi (Department of Medical Oncology, Toyama Prefectural Central Hospital) <b>切除不能進行・再発癌によるがん悪液質に対するアナモレリンの有効性と安全性の検討</b> 高木 宏明 (富山県立中央病院 腫瘍内科)
Room 2	16:45-17:30 Poster Session 54 / ポスターセッション 54	
Room 3	<b>P54</b> Translational Research/Clinical Pharmacology (Miscellaneous) TR・臨床薬理 (その他)	
Room 4	P54-1	<b>Identification of Breast Cancer Stem Cells by a newly developed fluorescence probe, C5S-A, targeted to ALDH1A1</b> Aoi Okamoto (Division of Breast and Endocrine Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan) 岡本 葵 (神戸大学 乳腺内分泌外科)
Room 5	P54-2	<b>Withaferin A and Caffeic Acid Phenethyl Ester combination possesses Anti-Metastasis Potential: Molecular Mechanisms</b> Renu Wadhwa (AIST-INDIA DAILAB, Cellular and Molecular Biology Research Institute, National Institute of Advanced Industrial Science & Technology (AIST))
Room 6	P54-3	<b>The model of spontaneous epithelial and mesenchymal plasticity characterized by CD44 expression in esophagus carcinoma</b> Kenji Tsuchihashi (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences / Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine) <b>食道癌におけるCD44発現に特徴づけられる上皮間葉転換の自然可塑性モデル</b> 土橋 賢司 (九州大学大学院医学研究院 病態修復内科学 / 慶應義塾大学医学部先端医学研究所遺伝子制御研究部門)
Room 7	P54-4	<b>Significance of GPT2 in cell proliferation and maintenance of stemness in gastric cancer cells</b> Kohei Arimizu (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan) 有水 耕平 (九州大学大学院医学研究院 病態修復内科学)
Room 8	Meet the Experts	
Room 9	Poster	

- P54-5 **Investigation of druggable protein phosphorylation in heterogeneity of glioma stem cells**  
Hisano Yanagi (Department of Medical Oncology, Fujita Health University School of Medicine)  
柳 久乃 (藤田医科大学医学部臨床腫瘍科)
- P54-6 **Nuclear IGF-1 receptor contributes to eribulin resistance in colorectal cancer**  
Tomoyasu Yoshihiro (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)  
吉弘 知恭 (九州大学 病態修復内科)
- P54-7 **RSK4 inhibition promotes pseudo-hypoxic metabolic response in lung adenocarcinoma**  
Lucksamon Thamlikitkul (Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University / Department of Surgery and Cancer, Imperial College London)
- P54-8 **Effect of metformin on cell proliferation, migration and apoptosis in T98G and NP5 cells**  
Teguh Priyadi Putra (Mochtar Riady Institute for Nanotechnology- Pelita Harapan University)
- P54-9 **Synergism of benzyl isothiocyanate with quercetin, caffeic acid and caffeine to kill cancer cells: Who cares?**  
Muhamad Hatib A Rahaman (Faculty of Marine Science and Environment, Universiti Malaysia Terengganu)
- P54-10 **Elucidating therapeutic effects of pazopanib in malignant phyllodes tumor in patient-derived xenografts and cell-lines**  
Jason Yongsheng Chan (Division of Medical Oncology, National Cancer Centre Singapore)
- P54-11 **Potential role of URST5 as a prognostic biomarker and therapeutic for oral cancer**  
Bayarbat Tsevegjav (Department of Medical Oncology, Shiga University of Medical Science / Ctr. for Advanced Med. against Cancer, Shiga Univ. of Med. Sci.)  
**口腔がんの新規予後マーカー、治療標的分子URST5の解析**  
シェベグジヤブ バヤルバット (滋賀医科大学 臨床腫瘍学/滋賀医科大学 先端がん研究センター)
- P54-12 **Molecular characterization of URST7 as a new prognostic biomarker and therapeutic target for breast cancer**  
Regina Mbugua (Shiga University of Medical Science, Dept.of Medical Oncology / Ctr. Advanced Med. against Cancer, Shiga Univ. of Med. Sci., Otsu, Shiga, Japan)  
ンボガ レジナ (滋賀医科大学/滋賀医科大学 先端がん研究センター)
- P54-13 **Involvement of URST4 protein in malignant nature of oral cancer**  
Ming Zhu (Dep. of Med. Oncol. & Cancer Ctr., Shiga Univ. Med. Sci. / Ctr. for Advanced Med. against Cancer, Shiga Univ. of Med. Sci.)  
祝 銘 (滋賀医科大学 臨床腫瘍学講座/滋賀医科大学 先端がん研究センター)
- P54-14 **Natural product nanoparticles induce drug resistance and a novel cell death in prostate cancer but can overcome**  
Qing Yang (Nazarbayev University)

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the Experts  
 Poster

16:45-17:30 Poster Session 55 / ポスターセッション 55

**P55 COVID-19 2**

- P55-1 **COVID-19 vaccination in gastrointestinal cancer patients during chemotherapy at a single institute experience**  
 Mitsukuni Suenaga (Department of Chemotherapy and Oncosurgery, Tokyo Medical and Dental University (TMDU))  
 末永 光邦 (東京医科歯科大学 消化器化学療法外科)
- P55-2 **An Analysis of Trends in Tele-prescription of anticancer agents during the COVID-19 pandemic**  
 Masami Tsuchiya (Department of Pharmacy, Miyagi Cancer Center)  
**COVID-19流行下における内服抗がん薬処方動向と電話処方の分析**  
 土屋 雅美 (宮城県立がんセンター)
- P55-3 **COVID-19 vaccine hesitancy among breast cancer patients: a pilot study**  
 Orielle Kyra B. Castro (Department of Internal Medicine, East Avenue Medical Center)
- P55-4 **COVID-19 vaccine hesitancy among breast cancer patients in East Avenue Medical Center**  
 Orielle Kyra B. Castro (Department of Internal Medicine, East Avenue Medical Center)
- P55-5 **King Hussein Cancer Center (KHCC) multi-dimensional contingency plan amid COVID-19**  
 Salma A. Samawi (King Hussein Cancer Foundation)
- P55-6 **A retrospective, single institutional analysis of outpatient chemotherapy in cancer patients during COVID-19 pandemic**  
 Yumiko Shimanuki (Department of Pharmacy, National Center for Global Health and Medicine)  
**COVID-19流行下における外来がん薬物療法施行状況の実態調査**  
 島貫 裕実子 (国立国際医療研究センター病院 薬剤部)
- P55-7 **COVID-19 Vaccination in Filipino cancer patients: Knowledge, attitudes, and safety outcomes**  
 Jessa gilda P. Panday (St. Luke's Medical Center / Cancer Institute, St. Luke's Medical Center, Philippines)

P56	Gastrointestinal Cancer (Colorectal Cancer 2) 消化器(大腸2)
P56-1	<p><b>FOLFIRI plus ramucirumab versus FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer</b> Mika Kitagawa (Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences) 北川 美香 (名古屋市立大学病院 消化器代謝内科学)</p>
P56-2	<p><b>Efficacy and safety of FTD/TPI+BV therapy in actual practice</b> Tatsuma Morikita (Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital) <b>実診療におけるFTD/TPI+BV療法の有効性と安全性</b> 森北 辰馬 (済生会熊本病院 総合腫瘍科)</p>
P56-3	<p><b>Ileostomy closure within 6 months after anterior resection for patients with indication of adjuvant chemotherapy</b> Zongyu Liang (Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital / Shantou University Medical College)</p>
P56-4	<p><b>Impact of Age on the Efficacy of Adjuvant Oxaliplatin Combination Therapy in Elderly Patients With Colorectal Cancer</b> Yusuke Nagata (Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Hospital / Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center) 永田 祐介 (東京慈恵会医科大学附属病院 消化器・肝臓内科 / 東京慈恵会医科大学 葛飾医療センター 消化器・肝臓内科)</p>
P56-5	<p><b>Usefulness of Ultrasonography and Elastography for Diagnosing of Sinusoidal obstruction syndrome induced by Oxaliplatin</b> Rika Saito (Division of Cancer Center, Hokkaido University Hospital) 斎藤 里佳 (北海道大学病院 腫瘍センター)</p>
P56-6	<p><b>Retrospective analysis of venous thromboembolism in patients with colorectal cancer at our hospital</b> Ayano Nakazono (Department of Gastroenterology, Tokyo metropolitan Tama Medical Center) <b>当院における結腸直腸がん患者の血栓塞栓症に関する後方視的検討</b> 中園 綾乃 (東京都立多摩総合医療センター 消化器内科)</p>
P56-7	<p><b>The Safety and feasibility for biweekly trifluridine/tipiracil plus bevacizumab regimen in advanced colorectal cancer</b> Hiroataka Inoue (Department of Clinical Research Planning and Management, Nagoya Medical Center Clinical Research Center / Department of Pharmacy, National Hospital Organization Nagoya Medical Center) 井上 裕貴 (名古屋医療センター 臨床研究センター 臨床研究企画管理部 / NHO名古屋医療センター 薬剤部)</p>
P56-8	<p><b>Migratory bone lesions that appeared after rectal cancer had healed</b> Hiroshi Tsukuda (Department of Oncology, Izumi General Hospital) <b>直腸がん治療後出現した骨の移動性病変</b> 佃 博 (和泉市立総合医療センター 腫瘍内科)</p>

- P56-9 **Single institute experiences of Cetuximab, Encorafenib ± Binimetinib for BRAF-mutated metastatic colorectal cancers**  
Masashi Nakamura (Department of Pharmacy, Cancer Institute Hospital, JFCR)  
中村 匡志 (公益財団法人 がん研究会有明病院 薬剤部)
- P56-10 **Clinical features of BRAF V600E mutated cases of colorectal cancer**  
Tadahiro Kamiya (Department of Surgery, Fujita Health University)  
**当科における大腸癌BRAFV600E変異症例の検討**  
神谷 忠宏 (藤田医科大学 総合消化器外科)
- 16:45-17:30 Poster Session 57 / ポスターセッション 57
- P57** **Gastrointestinal Cancer (Gastric Cancer 2)**  
消化器(胃2)
- P57-1 **Association of prophylactic dexamethasone during prior treatment with efficacy of nivolumab in advanced gastric cancer**  
Keisuke Baba (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)  
馬場 啓介 (国立がん研究センター中央病院)
- P57-2 **Nivolumab does not enhance the effect of subsequent chemotherapy in gastric cancer**  
Keitaro Doi (Department of Medical Oncology, Osaka Red Cross Hospital)  
土井 恵太郎 (大阪赤十字病院 腫瘍内科)
- P57-3 **Factors of the third-line treatment induction in advanced gastric cancer based on eligibility for clinical trials**  
Miho Sakumura (Third Department of Internal Medicine, University of Toyama)  
作村 美穂 (富山大学附属病院 第3内科)
- P57-4 **The prevalence of PD-L1 expression in HER2-positive advanced gastric cancer**  
Keitaro Shimozaki (Department of Gastroenterological chemotherapy, Cancer Institute Hospital of JFCR / Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)  
下嵯 啓太郎 (がん研究会有明病院 消化器化学療法科/慶應義塾大学医学部内科学教室(消化器))
- P57-5 **Impact of treatment with nivolumab on the survival of patients with advanced gastric cancer**  
Hiroo Katsuya (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)  
勝屋 弘雄 (佐賀大学医学部血液・呼吸器・腫瘍内科)
- P57-6 **Helicobacter pylori isolates from Mongolia describing gastric carcinogenesis and human migration**  
Gantuya Boldbaatar (Mongolia Japan Hospital of Mongolian National University of Medical Sciences / Department of Gastroenterology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia)
- P57-7 **Inflammatory scores in gastric cancer patients treated with nivolumab: Tokushukai REAL-world Data project 02(TREAD 02)**  
Rai Shimoyama (Department of General Surgery, Shonankamakura General Hospital)  
下山 ライ (湘南鎌倉総合病院 外科)



- P57-8 **A retrospective study of brain metastases in gastric cancer**  
Yasunobu Ishizuka (Osaka International Cancer Institution)  
石塚 保亘 (大阪国際がんセンター 腫瘍内科)
- P57-9 **Retrospective analysis of nivolumab in advanced gastric cancer patients with massive ascites**  
Kunihiro Tsuji (Department of Gastroenterology, Ishikawa Prefectural Central Hospital)  
辻 国広 (石川県立中央病院)

16:45-17:30 Poster Session 58 / ポスターセッション 58

**P58** Gastrointestinal Cancer (Miscellaneous)  
消化器(その他)

- P58-1 **The efficacy and safety of nivolumab for metastatic squamous cell carcinoma of the anal canal: a retrospective study**  
Toshiharu Hirose (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
廣瀬 俊晴 (国立がん研究センター中央病院 消化管内科)
- P58-2 **Rechallenge of dose reduced imatinib was effective to an elderly patient with c-kit positive GIST patient: a case report**  
Naoto Takase (Respiratory Medicine and Medical Oncology, Takarazuka City Hospital)  
**Imatinibの減量再開が有効であった高齢者のc-kit陽性直腸GIST患者の1例**  
高瀬 直人 (宝塚市立病院)

16:45-17:30 Poster Session 59 / ポスターセッション 59

**P59** Hepatobiliary/Pancreatic Cancer (Pancreatic Cancer-Miscellaneous 2)  
肝胆膵(膵臓-その他2)

- P59-1 **Identification of Germline Mutation Profiles in Pancreatic ductal adenocarcinoma by Whole Exome Sequencing**  
Siao Muk Cheng (National Institute of Cancer Research, National Health Research Institutes (NHRI), Taiwan)
- P59-2 **Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: a single institutional experience**  
Yu-lin Ting (Department of Oncology, National Cheng-Kung University Hospital, Tainan, Taiwan)
- P59-3 **False negative of KRAS mutation in comprehensive genome profiling test using circulating tumor DNA in pancreatic cancer**  
Dai Inoue (Department of Gastroenterology, Tokyo Metropolitan Tama Medical Center)  
**膵癌におけるリキッドバイオプシーでのKRAS遺伝子変異偽陰性の可能性の検討**  
井上 大 (東京都立多摩総合医療センター 消化器内科)
- P59-4 **Analysis of symptomatic venous thromboembolism after pancreatic cancer chemotherapy**  
Munehiro Wakabayashi (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University)  
**膵臓癌化学療法後に生じた症候性静脈血栓塞栓症の検討**  
若林 宗弘 (東邦大学医学部医学科内科学講座消化器内科学分野(大森))

Day 1 (Thu)	P59-5	<b>SAC3 domain containing 1 (SAC3D1) promotes pancreatic cancer development via regulation of EIF4A3</b> Kangsheng Peng (Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University)
Day 2 (Fri)	P59-6	<b>Mutation Status in PTEN Gene in X Ray-Induced Insulinoma Cell Line Rin-5F</b> Takayoshi Kiba (Department of Internal Medicine Saiseikai Kibi Hospital) 木場 崇剛 (済生会吉備病院)
Day 3 (Sat)	P59-7	<b>ten-year incidence of pancreatic carcinoma</b> Takamori Ogawa (Department of Medical Oncology) <b>当院における膵がん症例数の推移、他の消化器がんとの過去10年間の比較</b> 小川 隆守 (亀田総合病院腫瘍内科)
Room 1		
Room 2		
Room 3	16:45-17:30	Poster Session 60 / ポスターセッション 60
Room 3	<b>P60</b>	Lung Cancer/Thoracic Cancer (Chemo NSCLC) 呼吸器 (Chemo NSCLC)
Room 4	P60-1	<b>Safety and feasibility of hyper short-hydration using furosemide in cisplatin-based chemotherapy</b> Yasushi Fukuda (Department of Respiratory Medicine, Kurashiki Central Hospital) 福田 泰 (倉敷中央病院 呼吸器内科)
Room 5		
Room 6	P60-2	<b>Effect of PD-L1 expression on efficacy of docetaxel and ramucirumab combination therapy in patients with advanced NSCLC</b> Tomohiro Nakayama (Department of Medical Oncology, Kishiwada City Hospital) 中山 智裕 (岸和田市民病院 腫瘍内科)
Room 7		
Room 8	P60-3	<b>Phase II study of ramucirumab and docetaxel for NSCLC patients with malignant pleural effusion, an interim analysis</b> Shinnosuke Takemoto (Department of Respiratory Medicine, Nagasaki University Hospital) 竹本 真之輔 (長崎大学病院 呼吸器内科)
Room 9		
Room 10	P60-4	<b>Consideration of adverse event by platinum-based combination therapy of lung cancer patient with autoimmune disease</b> Ryosuke Morio (Department of Respiratory Medicine, Nagasaki University) 森尾 瞭介 (長崎大学病院呼吸器内科)
Room 11	16:45-17:30	Poster Session 61 / ポスターセッション 61
Room 12	<b>P61</b>	Lung Cancer/Thoracic Cancer (ICI efficacy 2) 呼吸器 (ICI 有効性2)
Room 13	P61-1	<b>Actual dose of nab-paclitaxel in KEYNOTE-407 regimen</b> Suguru Matsuda (Department of Pulmonary Medicine, Sendai Kousei Hospital) 松田 賢 (仙台厚生病院 呼吸器内科)
Meet the Experts	P61-2	<b>The efficacy of combination of chemotherapy and immunotherapy compared with immunotherapy alone for NSCLC</b> Satoshi Hirano (Department of Medical Oncology, Funabashi Municipal Medical Center) <b>非小細胞肺癌における免疫療法化学療法の併用療法と免疫療法の有用性の比較</b> 平野 聡 (船橋市立医療センター 腫瘍内科)
Poster		

P61-3	<p><b>The clinical outcomes of nivolumab plus ipilimumab combined with platinum-based chemotherapy for metastatic NSCLC</b>  Natsuko Komiya (Department of Internal Medicine, Faculty of Medicine, Saga University)  小宮 奈津子 (佐賀大学医学部附属病院)</p>
P61-4	<p><b>Efficacy and safety of atezolizumab for non-small cell lung cancer in a single-center study</b>  Takafumi Hashimoto (Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine)  <b>当院における非小細胞肺癌に対するアテゾリズマブの有効性と安全性の検討</b>  橋本 崇史 (大分大学医学部 呼吸器・乳腺外科学講座)</p>
P61-5	<p><b>Examination of patients with advanced non-small cell lung cancer (NSCLC) responding to nivolumab monotherapy over 1 year</b>  Saki Nakajima (Department of Thoracic Medical Oncology, National Hospital Organization, Osaka Minami Medical Center)  <b>当院においてニボルマブの単剤投与により長期奏効を得られた非小細胞肺癌患者の検討</b>  中島 早希 (大阪南医療センター 呼吸器腫瘍内科)</p>
P61-6	<p><b>悪性胸膜中皮腫に対するニボルマブ リチャレンジ症例の検討</b>  Mayuko Tokuda (Department of Respiratory Medicine and Hematology Hyogo College of Medicine)  徳田 麻佑子 (兵庫医科大学 呼吸器・血液内科学)</p>
P61-7	<p><b>KEYNOTE-A86: Phase 3 Study of 1L Subcutaneous vs Intravenous Pembrolizumab with Platinum Chemo in Metastatic NSCLC</b>  Takayasu Kurata (Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan)  倉田 宝保 (関西医科大学附属病院 呼吸器腫瘍内科)</p>
16:45-17:30 Poster Session 62 / ポスターセッション 62	
<b>P62</b>	<b>Lung Cancer/Thoracic Cancer (Locally advanced)</b> 呼吸器(局所 NSCLC)
P62-1	<p><b>Durvalumab for patients with stage III NSCLC and Grade 1 radiation pneumonitis: multicenter prospective cohort study</b>  Takashi Yokoi (Department of Thoracic Oncology, Hyogo College of Medicine)  横井 崇 (兵庫医科大学 胸部腫瘍学特定講座)</p>
P62-2	<p><b>Association of survival and tumor marker value fluctuation during CRT in patients with unresectable stage III NSCLC</b>  Momoko Morishita (Department of Respiratory Medicine, National Cancer Center Hospital)  森下 桃子 (国立がん研究センター中央病院 呼吸器内科)</p>
P62-3	<p><b>Change in plasma level of damage-associated molecular patterns due to chemoradiotherapy in locally advanced NSCLC</b>  Yoshiro Nakahara (Department of Respiratory Medicine, Kitasato University School of Medicine / Department of Thoracic Oncology, Kanagawa Cancer Center)  中原 善朗 (北里大学医学部 呼吸器内科学 / 神奈川県立がんセンター 呼吸器内科)</p>

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

P62-4 **Analysis of factors predictive of long-term PFS after concurrent chemo-proton therapy in inoperable stage III NSCLC**  
 Kazuki Yamada (Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University Graduate School of Medical Sciences, West Medical Center)  
 山田 一貴 (名古屋市立大学医学部附属西部医療センター 呼吸器腫瘍センター 呼吸器内科)

P62-5 **Concurrent chemoradiotherapy using cisplatin/s-1 followed by durvalumab in clinical practice of a regional hospital**  
 Yukio Kawagishi (Department of Respiratory Medicine, Kurobe City Hospital)  
 河岸 由紀男 (黒部市民病院)

P62-6 **S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma (LOGIK1605/JART1501)**  
 Minoru Fukuda (Clinical Oncology Center, Nagasaki University Hospital)  
**局所進行胸腺癌に対するS-1とシスプラチンによる化学放射線同時併用療法の第2相試験 (LOGIK1605/JART1501)**  
 福田 実 (長崎大学病院がん診療センター)

16:45-17:30 Poster Session 63 / ポスターセッション 63

**P63** Lung Cancer/Thoracic Cancer (Perioperative)  
 呼吸器 (周術期)

P63-1 **Safety and efficacy of Stereotactic Body Radiotherapy in patient with early stage NSCLC : Systematic review**  
 Mohammad Z. Sabran (Faculty of Medicine, Pelita Harapan University)

P63-2 **Platelet Count as a Prognostic Marker for Survival in Non-small-cell Lung Cancer Patients**  
 Mohammad Salman Hussain (Faculty of Medicine, Masaryk University)

P63-3 **Prognostic impact of post-operative CNS recurrence in patients with EGFR-mutation positive non-small cell lung cancer**  
 Tatsuro Okamoto (Department of Thoracic Oncology, NHO Kyushu Cancer Center)  
 岡本 龍郎 (国立病院機構 九州がんセンター)

P63-4 **A phase II study of adjuvant chemotherapy with docetaxel plus nedaplatin for completely resected NSCLC**  
 Koji Teramoto (Department of Medical Oncology, Shiga University of Medical Science / Cancer for Advanced Medicine against Cancer, Shiga University of Medical Science)  
 寺本 晃治 (滋賀医科大学 臨床腫瘍学講座 (腫瘍内科) / 滋賀医科大学 先端がん研究センター)

P63-5 **Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR-mutated resectable NSCLC: NeoADAURA**  
 Yasushi Yatabe (Department of Diagnostic Pathology, National Cancer Center)  
 谷田部 恭 (国立がん研究センター 中央病院 病理診断科)

P64	Rare Cancer/Cancer of Unknown Primary (Case Report 3) 希少がん・原発不明がん(ケースレポート3)	
P64-1	<b>Seminoma in androgen insensitivity syndrome: a case report</b> Orielle Kyra B. Castro (Department of Internal Medicine, East Avenue Medical Center)	Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster
P64-2	<b>Mucinous Cystic Neoplasm of the Liver with Ectopic Pancreas : A Case Report</b> Tanwimon Techasatian (Department of Internal Medicine, Sikarin Hospital)	
P64-3	<b>Primary DICER1 associated CNS sarcoma: a case report</b> Ryoji Tanaka (Department of Medical Oncology, National Cancer Center Hospital) <b>Primary DICER1 associated CNS sarcomaの一例</b> 田中 亮嗣 (国立がん研究センター中央病院 腫瘍内科)	
P64-4	<b>A case of follicular dendritic cell sarcoma successfully treated with doxorubicin monotherapy</b> Yoji Fuchizaki (National Hospital Organization Kyushu Cancer Center) <b>ドキシソルピシン単剤が著効した濾胞樹状細胞肉腫の一例</b> 瀧崎 蓉史 (九州がんセンター)	
P64-5	<b>A case of thymoma with systemic capillary leak syndrome that responded to high-dose steroid therapy</b> Masashi Namba (Department of Clinical Oncology, Hiroshima University Hospital) <b>大量ステロイド療法が有効であった全身性毛細血管漏出症候群を随伴した胸腺腫の1例</b> 難波 将史 (広島大学病院 がん化学療法科)	
P64-6	<b>A case of advanced rectal cancer transformed from adenocarcinoma to choriocarcinoma</b> Kentaro Tokumo (Department of Clinical Oncology, Hiroshima University Hospital) <b>腺癌から絨毛癌に形質転換した進行直腸癌の1例</b> 徳毛 健太郎 (広島大学病院がん化学療法科)	
P64-7	<b>化学療法が奏効した家族性大腸腺腫症に合併したデスマイド腫瘍の一例</b> Shinichiro Matsuda (Department of Medical Oncology, Shimane University Hospital) 松田 真一郎 (島根大学医学部附属病院)	
P64-8	<b>A long-term survival case of cardiac angiosarcoma treated with Resection followed by Radiotherapy and Chemotherapy</b> Shinya Kobayashi (Department of Hematology and Oncology, Nara Prefecture General Medical Center) <b>集学的治療により長期生存が得られた心臓血管肉腫の1例</b> 小林 真也 (奈良県総合医療センター 血液・腫瘍内科)	
P64-9	<b>Small intestine cancer diagnosed due to bilateral ovarian swelling: A case report</b> Manabu Seino (Department of Obstetrics and Gynecology, Yamagata University) <b>卵巣腫大を契機に診断に至った小腸癌の1例</b> 清野 学 (山形大学医学部附属病院)	
P64-10	<b>A case of malignant granular cell tumor, long term disease control with pazopanib</b> Seguchi Seguchi (Department of Medical Oncology, Kameda General Hospital) <b>Pazopanib rechallengeで長期の病勢制御を得た悪性顆粒細胞腫の一例</b> 瀬口 京介 (亀田総合病院 腫瘍内科)	